Method for the chemical synthesis of oligonucleotides

ABSTRACT

The present invention features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof.

This invention is a continuation-in-part of Vargeese et al., U.S. Ser.No. 09/426,079, filed Oct. 22, 1999, entitled “METHOD FOR THE CHEMICALSYNTHESIS OF RNA”, which claims priority from Vargeese et al., U.S. Ser.No. 09/178,154, filed Oct. 23, 1998, entitled “METHOD FOR THE CHEMICALSYNTHESIS OF RNA”.

BACKGROUND OF THE INVENTION

This invention relates to a novel method for the chemical synthesis ofoligonucleotides, including RNA, DNA, chimeric oligonucleotides, andchemically modified nucleic acids. Specifically, the invention concernsnovel processes for synthesis of oligonucleotides using controlled poreglass solid support.

The following is a discussion of relevant art, none of which is admittedto be prior art to the present invention.

Chemical synthesis of oligonucleotides can be accomplished using anumber of protocols, including the use of solid support chemistry, wherean oligonucleotide is synthesized one nucleoside at a time whileanchored to an inorganic polymer. The first nucleotide is attached to aninorganic polymer using a reactive group on the polymer, which reactswith a reactive group on the nucleoside to form a covalent linkage. Eachsubsequent nucleoside is then added to the first nucleoside moleculeby: 1) formation of a phosphite linkage between the original nucleosideand a new nucleoside with a protecting group; 2) conversion of thephosphite linkage to a phosphate linkage by oxidation; and 3) removal ofone of the protecting groups to form a new reactive site for the nextnucleoside (Caruthers & Matteucci, U.S. Pat. No. 4,458,066; U.S. Pat.No. 5,153,319; U.S. Pat. No. 5,132,418; U.S. Pat. No. 4,973,679 all ofwhich are incorporated by reference herein). Solid phase synthesis ofoligonucleotides eliminates the need to isolate and purify theintermediate products after the addition of every nucleotide base.

Following the synthesis of RNA, the oligonucleotides is deprotected(Wincott et al., supra) and purified to remove by-products, incompletesynthesis products, and the like.

The demand for oligonucleotides for use as therapeutic agents,diagnostics, and research reagents has created the need for theefficient cost effective large scale manufacture of these compounds.Currently, efforts have focused on improving the coupling efficiency andthe maximization of yield in phosphoramidite based synthesis. However,another area that deserved attention in this approach is the overalltime and cost of preparing the nucleoside phosphoramidite reagents to beused as raw materials in the manufacture of oligonucleotides. The use ofin situ phosphoramidite generation in the synthesis of oligonucleotidesis an attempt to overcome the limitations imposed on the synthesis andisolation of phosphoramidites. By generating reactive nucleosideintermediates during the actual synthesis of the oligonucleotide, theneed for separate phosphoramidite manufacture is overcome. However,efforts thus far have relied upon the in situ generation of5′-O-protected nucleoside 3′-O-phosphoramidites that are coupled with5′-OH nucleophiles. This approach is problematic in that dimerization ofthe intended 5′-O-protected nucleoside 3′-O-phosphoramidites occurs as acompeting reaction, thereby reducing the effective equivalents ofphosphoramidite available for coupling.

Tracz, U.S. Pat. No. 5,686,599, describes a method for one potdeprotection of RNA under conditions suitable for the removal of theprotecting group from the 2′ hydroxyl position.

Usman et al., U.S. Pat. No. 5,804,683, describes a method for theremoval of exocyclic protecting groups using alkylamines.

Wincott et al., U.S. Pat. No. 5,831,071, describes a method for thedeprotection of RNA using ethylamine, propylamine, or butylamine.

Vinayak, U.S. Pat. No. 5,281,701, describes methods and reagents for thesynthesis of RNA using 5′-O-protected-2′-O-alkylsilyl-adenosinephosphoramidite and 5′-O-protected-2′-O-alkylsilylguanosinephosphoramidite monomers which are deprotected using ethylthiotetrazole.

Usman and Cedergren, Trends in Biochem. Sci. 1992, 17, 334-339 describethe synthesis of RNA-DNA chimeras for use in studies of the role of 2′hydroxyl groups.

Sproat et al., 1995 Nucleosides & Nucleotides 14, 255-273, describe theuse of 5-ethylthio-1H-tetrazole as an activator to enhance the qualityof oligonucleotide synthesis and product yield.

Gait et al., 1991, Oligonucleotides and Analogues, ed. F. Eckstein,Oxford University Press 25-48, describe general methods for thesynthesis of RNA.

Koester and Coull, U.S. Pat. No. 4,923,901; Klem and Riley, U.S. Pat.No. 5,723,599; Furukawa et al., U.S. Pat. No. 5,674,856; Nelson, U.S.Pat. No. 5,141,813; Reed et al., U.S. Pat. No. 5,419,966; Caruthers andMatteucci, U.S. Pat. No. 4,458,066; Bhatt, U.S. Pat. No. 5,252,723;Weetall et al., 1974, Methods in Enzymology, 34, 59-72; Van Aerschot etal., 1988, Nucleosides and Nucleotides, 7, 75-90; Maskos and Southern,1992, Nucleic Acids Research, 20, 1679-1684; Van Ness et al., 1991,Nucleic Acids Research, 19, 3345-3350; Katzhendler et al., 1989,Tetrahedron, 45, 2777-2792; Hovinen et al., 1994, Tetrahedron, 50,7203-7218; Nippon Shinyaku, GB 2,169,605; Boehringer Mannheim, EP325,970; Reddy and Michael, International PCT publication No. WO94/01446; Akad. Wiss. DDR, E. German patent No. 280,968; and Bayer, W.German patent No. 4,306,839, all describe specific examples of solidsupports for oligonucleotide synthesis and specific methods of use forcertain oligonucleotides.

Zhang and Tang, International PCT Publication No. WO 97/42202; andKitamura et al., 2000, Chem Lett., 10, 1134-1135 describe specificphosphitylating reagents and their use in oligonucleotide synthesis viain situ generation of 5′-β-protected nucleoside 3′-O-phosphoramidites.

SUMMARY OF THE INVENTION

The present invention features compounds and reagents useful in thesynthesis of oligonucleotides.

The efficiency of oligonucleotide synthesis is influenced by a number ofvariables including the form of solid support utilized, the length andtype of spacer, and the type of chemical bond utilized as a linkerbetween the spacer and the first nucleoside (Katzhendler et al., 1989,Tetrahedron 45, 2777-2792). The effects of modifying the spacer lengthhas been investigated to determine the optimal length for efficientsynthesis of DNA oligonucleotides (Katzhendler et al., 1987, ReactivePolymers 6, 175-187; Katzhendler et al, 1989, Tetrahedron 45, 2777).

For example Katzhendler et al, 1989, supra, state that for the synthesisof DNA:

“[s]pacers made up of only 12-21 atoms in length, produced poor resultsrelatives to end product purity, homogeneity and yield. Purer productswere obtained on spacers with lengths of at least 24 atoms”.

The authors further indicate that the efficiency of DNA synthesis willbe relatively high so long as the spacer length is at least 24 atoms.They further suggest that the poor efficiency of DNA synthesis using12-24 atom spacers is caused by a tendency of these spacers to bendtowards the solid support. The bent spacer would allow for increasedstabilization of the solid support due to inter-chain stabilization, butwould negatively impact DNA oligonucleotide synthesis.

Applicant has surprisingly found that the use of specific spacers havinglengths between about 9 to about 24 atoms can be utilized for theefficient synthesis of oligonucleotides. These spacers have beenutilized by applicant to produce high yields of oligonucleotides withincreased purity.

In one embodiment, the invention features derivatized solid supportcompositions useful in the synthesis of oligonucleotides and methods ofuse, wherein the derivatized solid support comprises a spacer moleculeof about 9-24 atoms in length.

In another embodiment, the invention features a compound having FormulaI:

wherein SP represents a solid support comprising controlled pore glass;polystyrene; silica gel; cellulose paper; polyamide/kieselgur; orpolacryloylmorpholide, n is an integer from about 1 to about 6, Brepresents a terminal chemical group, for example a nucleic acid,nucleoside, nucleotide, or non-nucleosidic derivative with or withoutprotecting groups, and W represents a chemical linkage, for example asuccinyl, oxalyl, hydroquinone-O—O′-diacetic acid, or photolabilelinker. W and B together can comprise a terminal chemical group, forexample a 5-O-succinyl-3-O-dimethoxytrityl nucleoside or abasicderivative.

In another embodiment, the invention features a compound having FormulaII:

wherein SP represents a solid support, for example controlled poreglass; polystyrene; silica gel; cellulose paper; polyamide/kieselgur; orpolacryloylmorpholide, n is an integer from about 1 to about 6, Brepresents a terminal chemical group, for example a nucleic acid,nucleoside, nucleotide, or non-nucleosidic derivative with or withoutprotecting groups, and W represents a chemical linkage, for example asuccinyl, oxalyl, hydroquinone-O—O′-diacetic acid, or photolabilelinker. W and B together can comprise a terminal chemical group, forexample a 5-O-succinyl-3-O-dimethoxytrityl nucleoside or abasicderivative.

In another embodiment, the invention features a compound having FormulaIII:

wherein SP represents a solid support, for example controlled poreglass; polystyrene; silica gel; cellulose paper; polyamide/kieselgur; orpolacryloylmorpholide, n is an integer from about 1 to about 6, Brepresents a terminal chemical group, for example a nucleic acid,nucleoside, nucleotide, or non-nucleosidic derivative with or withoutprotecting groups, and W represents a chemical linkage, for example asuccinyl, oxalyl, hydroquinone-O—O′-diacetic acid, or photolabilelinker. W and B together can comprise a terminal chemical group, forexample a 5-O-succinyl-3-O-dimethoxytrityl nucleoside or abasicderivative.

In another embodiment, the invention features a compound having FormulaIV:

wherein SP represents a solid support, for example controlled poreglass; polystyrene; silica gel; cellulose paper; polyamide/kieselgur; orpolacryloylmorpholide, n is an integer from about 1 to about 6, Brepresents a terminal chemical group, for example a nucleic acid,nucleoside, nucleotide, or non-nucleosidic derivative with or withoutprotecting groups, and W represents a chemical linkage, for example asuccinyl, oxalyl, hydroquinone-O—O′-diacetic acid, or photolabilelinker. W and B together can comprise a terminal chemical group, forexample a 5-O-succinyl-3-O-dimethoxytrityl nucleoside or abasicderivative.

In one embodiment, the invention features a compound having Formula V:

wherein SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide, and n is an integer fromabout 1 to about 6.

In another embodiment, the invention features a compound having FormulaVI:

wherein SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide, and n is an integer fromabout 1 to about 6.

In another embodiment, the invention features a compound having FormulaVII:

wherein SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide, and n is an integer fromabout 1 to about 6.

In another embodiment, the invention features a compound having FormulaVIII:

wherein SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide, and n is an integer fromabout 1 to about 6.

In another embodiment the invention features a method (“method A”) forsolid phase synthesis of oligonucleotides comprising: 5′-deblocking,coupling, oxidation, and capping, wherein these steps are repeated underconditions suitable for the synthesis of an oligonucleotide, and whereinthe synthesis of the oligonucleotide is initiated on a derivatized solidsupport linked to a terminal chemical group via a spacer molecule,wherein the derivatized solid support linked to the terminal chemicalgroup comprises a structure having Formula I, II, III or IV.

In another embodiment the invention features a method (“method B”) forsolid phase synthesis of oligonucleotides comprising: 5′-deblocking,coupling, oxidation, and capping, wherein these steps are repeated underconditions suitable for the synthesis of an oligonucleotide, and whereinthe synthesis of the oligonucleotide is initiated on a derivatized solidsupport linked to a terminal chemical group via a spacer molecule,wherein the derivatized solid support linked to the terminal chemicalgroup comprises a structure having Formula IX:

SP—X—W—B  IX

wherein, SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide; X represents a spacercomprising a linear chemical moiety Y-Z-W comprised of carbon, silicon,hydrogen, nitrogen, sulfur, and/or oxygen atoms where Z is a diradicalchemical moiety of between 10 and 24 atoms, preferably 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 atoms, Y and Windependently comprise a chemical linkage, wherein the chemical linkageY between SP and X comprises a silyl ether, urea, amide, or carbamatelinkage and the chemical linkage W between the X and B comprises acarboxy, amino, carboxamido, mercaptoalkyl, succinyl, oxalyl, orphotolabile linker (e.g. 3′ glycolate termini,o-nitrophenyl-1,3-propanediol), acid labile linker (e.g.alkoxybenzylidene acetal, hydroquinone-O,O′-diacetic acid), orpentachlorophenyl-succinate, (Pon et al., 1988, Biotechniques 6,768-775; Palom et al., 1993, Tetrahedron Lett. 34, 2195-2198; Greenberg,1995, Tetrahedron 51, 29-38; Hovinen et al., 1994, Tetrahedron 50,7203-7213; Palom et al., 1991, Tetrahedron Lett 34, 2195-2198; Pon & Yu,1997, Tetrahedron Lett 38, 3327-3330; Dell-Aquila et al., 1997,Tetrahedron Lett. 38, 5289-5292; Birch-Hirschfeld et al., 1994, NucleicAcids Research 22, 1760-1761; Alul et al., 1991, Nucleic Acids Research19, 1527-1532, all of which are incorporated by reference herein intheir entirety); B represents a terminal chemical group, such as, forexample, a nucleic acid, nucleoside, nucleotide, or non-nucleosidicderivative with or without protecting groups. W and B together cancomprise a terminal chemical group, for example a5-O-succinyl-3-O-dimethoxytrityl nucleoside or abasic derivative, whereB can be linked to the oligonucleotide being synthesized via 3′-5′,3′-2′, or 3′-3′ linkages. Non-limiting examples of general formulae forspacers of the present invention are given in FIG. 8.

In another embodiment the invention features a method (“method C”) forsolid phase synthesis of oligonucleotides comprising: 5′-deblocking,5′-activation, coupling, oxidation, and capping, wherein these steps arerepeated under conditions suitable for the synthesis of anoligonucleotide, and wherein 5′-activation comprises the in situformation of an activated 5′-phosphorus species and coupling comprisesthe nucleophilic attack of the activated 5′-phosphorus species underconditions suitable for covalent attachment of the nucleophile to theactivated 5′-phosphorus species, and wherein the synthesis of theoligonucleotide is initiated on a derivatized solid support linked to aterminal chemical group via a spacer molecule, wherein the derivatizedsolid support linked to the terminal chemical group comprises astructure having Formula I, II, III or IV.

In another embodiment the invention features a method (“method D”) forsolid phase synthesis of oligonucleotides comprising: 5′-deblocking,5′-activation, coupling, oxidation, and capping, wherein these steps arerepeated under conditions suitable for the synthesis of anoligonucleotide, and wherein 5′-activation comprises the in situformation of an activated 5′-phosphorus species and coupling comprisesthe nucleophilic attack of the activated 5′-phosphorus species underconditions suitable for covalent attachment of the nucleophile to theactivated 5′-phosphorus species, and wherein the synthesis of theoligonucleotide is initiated on a derivatized solid support linked to aterminal chemical group via a spacer molecule, wherein the derivatizedsolid support linked to the terminal chemical group comprises astructure having Formula IX:

SP—X—W—B  IX

wherein, SP represents a solid support, for example controlled poreglass; nylon, polystyrene; silica gel; cellulose paper;polyamide/kieselgur; or polacryloylmorpholide; X represents a spacercomprising a linear chemical moiety Y-Z-W comprised of carbon, silicon,hydrogen, nitrogen, sulfur, and/or oxygen atoms where Z is a di-radicalchemical moiety of between 10 and 24 atoms, preferably 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 atoms, Y and Windependently comprise a chemical linkage, wherein the chemical linkageY between SP and X comprises a silyl ether, urea, amide, or carbamatelinkage and the chemical linkage W between the X and B comprises acarboxy, amino, carboxamido, mercaptoalkyl, succinyl, oxalyl, orphotolabile linker (e.g. 3′ glycolate termini,o-nitrophenyl-1,3-propanediol), acid labile linker (e.g.alkoxybenzylidene acetal, hydroquinone-O, O′-diacetic acid), orpentachlorophenyl-succinate, (Pon et al., 1988, Biotechniques 6,768-775; Palom et al., 1993, Tetrahedron Lett. 34, 2195-2198; Greenberg,1995, Tetrahedron 51, 29-38; Hovinen et al., 1994, Tetrahedron 50,7203-7213; Palom et al., 1991, Tetrahedron Lett 34, 2195-2198; Pon & Yu,1997, Tetrahedron Lett 38, 3327-3330; Dell-Aquila et al., 1997,Tetrahedron Lett. 38, 5289-5292; Birch-Hirschfeld et al., 1994, NucleicAcids Research 22, 1760-1761; Alul et al., 1991, Nucleic Acids Research19, 1527-1532, all of which are incorporated by reference herein intheir entirety); B represents a terminal chemical group, for example anucleic acid, nucleoside, nucleotide, or non-nucleosidic derivative withor without protecting groups. W and B together can comprise a terminalchemical group, for example a 5-O-succinyl-3-O-dimethoxytritylnucleoside or abasic derivative, where B can be linked to theoligonucleotide being synthesized via 3′-5′, 3′-2′, or 3′-3′ linkages;Non-limiting examples of general formulae for spacers of the presentinvention are given in FIG. 8.

In one embodiment, “B” of Formulae I, II, III, IV and IX comprises anucleic acid, nucleoside, nucleotide, or non-nucleosidic derivativecomprising an acid labile protecting group, for example adimethoxytrityl, monomethoxytrityl, or other trityl group.

In another embodiment, the chemical linkage “W” between “B” of FormulaeI, II, III, IV and IX and the spacer molecule “X” comprises a succinyllinker.

In another embodiment, “X” in Formula IX comprises Formula X:

wherein n is an integer from about 1 to about 6.

In another embodiment, “X” in Formula IX comprises Formula XI:

wherein n is an integer from about 1 to about 6.

In another embodiment, “X” in Formula IX comprises Formula XII:

wherein n is an integer from about 1 to about 6.

In one embodiment, the invention features a method of synthesizing acompound having Formula V, where n=3, comprising silanization of nativeControlled Pore Glass (CPG) with N-(6-aminohexyl)aminopropyl trimethoxysilane under conditions suitable for the formation of a compound havingFormula V.

In another embodiment, the coupling of the terminal chemical group B tothe compound of Formula V results in a compound of Formula I. In yetanother embodiment, the coupling of the terminal chemical group B to thecompound of Formula V is at a loading from about 50 to about 100umol/gram of CPG, or about 75 to about 85 umol/gram of CPG.

In another embodiment, the coupling of the terminal chemical group B tothe compound of Formula VI results in a compound of Formula II. In yetanother embodiment, the coupling of the terminal chemical group B to thecompound of Formula VI is at a loading from about 40 to about 80umol/gram of CPG, or about 50 to about 60 umol/gram of CPG.

In another embodiment, the coupling of the terminal chemical group B tothe compound of Formula VII results in a compound of Formula III. In yetanother embodiment, the coupling of the terminal chemical group B to thecompound of Formula VII is at a loading from about 40 to about 80umol/gram of CPG, or about 50 to about 60 umol/gram of CPG.

In another embodiment, the coupling of the terminal chemical group B tothe compound of Formula VIII results in a compound of Formula IV. In yetanother embodiment, the coupling of the terminal chemical group B to thecompound of Formula VIII is at a loading from about 40 to about 80umol/gram of CPG, or about 50 to about 60 umol/gram of CPG.

In one embodiment, the invention features a method (Method E) for thesynthesis of oligonucleotides comprising: 5′-deblocking, 5′-activation,coupling, oxidation, and capping, wherein these steps are repeated underconditions suitable for the synthesis of an oligonucleotide, and wherein5′-activation comprises the in situ formation of an activated5′-phosphorus species and coupling comprises the nucleophilic attack ofthe activated 5′-phosphorus species under conditions suitable forcovalent attachment of the nucleophile to the activated 5′-phosphorusspecies.

In another embodiment, the 5′-activation contemplated by the inventioncomprises the in situ formation of a nucleoside 5′-O-phosphoramidite. Inyet another embodiment, the nucleoside 5′-O-phosphoramidite of theinvention is 5′-O-nucleoside2-cyanoethyl-N,N-diisopropylphosphoramidite.

In another embodiment, the 5′-activation contemplated by the inventioncomprises the in situ formation of a nucleoside 5′-O—H-phosphonate,5′-β-phosphotriester, 5′-O-pyrophosphate, or 5′-O-phosphate, wherein theoxidation step is either optional or omitted altogether.

In one embodiment, the 5′-activation contemplated by the inventioncomprises conjugation of a nucleoside 5′-hydroxyl with a phosphine inthe presence of an activator. In another embodiment, the phosphinecontemplated by the invention comprisescyanoethyl-(bis)-N,N-diisopropylphosphoramidite (2-cyanoethyltetraisopropylphosphorodiamidite) and the activator comprises S-ethyltetrazole (SET), tetrazole, or dicyanoimidazole (DCI).

In another embodiment, the 5′-activation contemplated by the inventioncomprises conjugation of a nucleoside 5′-hydroxyl with a phosphate inthe presence of an activator. In another embodiment, the phosphatecontemplated by the invention comprises a 2-chlorophenylphosphorodichloridate or 2,5-dichlorophenyl phosphorodichloridate andthe activator comprises 1-(mesitylsulfonyl)-3-nitro-1,2,4-1H-triazole(MSNT).

In another embodiment, the method for the synthesis of oligonucleotidescomprising: 5′-deblocking, 5′-activation, coupling, oxidation, andcapping is a solid phase synthesis, solution phase synthesis, or mixedphase synthesis.

In yet another embodiment, solid phase synthesis via Methods A-E of theinvention is carried out on a solid support comprising silicon-basedchips, controlled pore glass; polystyrene; nylon, silica gel; cellulosepaper; polyamide/kieselgur; or polacryloylmorpholide.

In one embodiment, the conditions suitable for covalent attachment ofthe nucleophile to the activated 5′-phosphorus species in Method E ofthe invention comprises the use of an activator, or example S-ethyltetrazole (SET), tetrazole, or dicyanoimidazole (DCI), in the presenceof a 5′-protected or 5′-protected N-protected nucleoside bearing anucleophile such as a hydroxyl group.

In one embodiment, Methods A-E of the invention are carried out on areaction scale of about 0.1 umol to about 100 umol.

In another embodiment, Methods A-E of the invention are carried out on areaction scale of about 100 umol to about 1 mmol.

In yet another embodiment, Methods A-E of the invention are carried outon a reaction scale of about 1 mmol to about 1 mol.

In yet another embodiment, Methods A-E of the invention are carried outon a reaction scale of about 1 mol to about 1000 mol.

In another, Methods A-E of the invention are carried out on a reactionscale of 3 to 300 mmol.

In one embodiment, Methods A-E of the invention is carried out on aoligonucleotide synthesizer, such as a flow through reactor or batchreactor synthesis platform, for example a Pharmacia OligoPilot,OligoProcess, Oligo-Max or AKTA synthesizer, Millipore 8800, or ABI 390Zplatform.

In another embodiment, Methods A and B of the invention utilize betweenabout 1.1 to about 2.0 equivalents of nucleoside phoshoramidite percoupling.

In yet another embodiment, Methods A and B of the invention utilizebetween about 2 to about 10 equivalents of activator per coupling.

In one embodiment, Methods C, D and E of the invention utilize betweenabout 1.1 to about 10 equivalents of phosphine per coupling.

In yet another embodiment, Methods C, D and E of the invention utilizebetween about 1.1 to about 20 equivalents of activator per activation.

In another embodiment, the 5′-deblocking and 5′-activation stepscontemplated by the invention can be applied to other positions within anucleoside or non-nucleoside compound, for example when an invertednucleoside or abasic derivative is included in the oligonucleotide. Insuch cases, 5′-deblocking and/or 5′-activation refers to the deblockingand activation of the corresponding group, such as a hydroxyl, that isintended to be substituted.

In one embodiment, “n” in Formula I of the invention is 3, “n” inFormula II of the invention is 6, “n” in Formula III of the invention is3 or 6, or “n” in Formula IV of the invention is 3 or 6.

The number of atoms referred to in the spacer molecules contemplated bythe invention, for example the Z component of “X” in Formula IX, refersto the number of linear atoms comprising the di-radical moiety thatconnects the solid support to the terminal chemical group, excluding thenumber of atoms in the chemical linker “W”. For example, the Z componentof “X” in Formula IX can comprise between 10 and 24 atoms. In anothernon-limiting example, a compound of Formula I, where n=3, is referred toas a 13 atom spacer molecule, since the spacer component of the moleculehas nine carbon atoms, such a molecule can be referred to, for example,as a 13 atom C9 molecule.

The term “succinyl”, “succinate” or “succinyl” linker as used hereinrefers to a structure as is known in the art comprising Formula XIII:

including any salts thereof, for example triethylamine salts, whereinthe succinate can comprise, for example a dimethoxytrityl (DMT)protected nucleoside (R₁) succinate such as 5′-O-DMT-3′-O-succinyluridine, cytidine, thymidine, adenosine or guanosine or anon-nucleosidic (R₁) succinate such as a5′-O-succinyl-3-O-dimethoxytrity deoxyribose derivative, where R₂ is Hor a linker molecule attached to a solid support.

The structure:

as used herein refers to a cyclohexane ring comprising para substitutionin a cis or trans configuration.

The structure:

as used herein refers to a linear alkyl di-radical, wherein the lengthof the alkyl chain is specified by the number of carbons atoms shown,for example by the actual number of carbon atoms in the molecule or bythe number of carbon atoms as determined by the integer value of “n”.Compounds of the invention can include both saturated and unsaturatedhydrocarbon chains in their structure, however, the exemplary structuresshown comprise saturated hydrocarbon chains.

The term “protected” as used herein refers to a chemical moiety that istemporarily attached to a reactive chemical group to prevent thesynthesis of undesired products during early stages of synthesis. Theprotecting group can then be removed to allow for the desired synthesisto proceed. Non-limiting examples of protecting groups are trityl,silyl, and acetyl groups.

The term “5′-deblocking” as used herein refers to a step in thesynthesis of an oligonucleotide wherein a protecting group is removedfrom the terminal chemical group or previously added nucleoside, toproduce a reactive hydroxyl, capable of contacting and reacting with anucleoside molecule, for example a nucleoside phosphoramidite. Oneexample of a protecting group that is removed is a trityl group, such asa dimethoxytrityl group.

The term “5′-activation” as used herein refers to a step in thesynthesis of an oligonucleotide wherein an activated 5′-phosphorusspecies is generated in situ, for example when a nucleoside 5′-hydroxylis conjugated with a phosphine or phosphate in the presence of anactivator.

The term “coupling” as used herein refers to a step in the synthesis ofan oligonucleotide wherein a nucleoside is covalently attached to thesolid support or the terminal nucleoside residue of the oligonucleotide,for example via nucleophilic attack of an activated nucleosidephosphoramidite, H-phosphonate, phosphotriester, pyrophosphate, orphosphate in solution by a terminal 5′-hydroxyl group of the supportbound nucleotide or oligonucleotide. The nucleoside phosphoramidite canbe activated by using an activator reagent such as but not limited to,tetrazole, S-ethyl tetrazole, and/or 4,5-dicyanoimidazole (DCI).

The term “oxidation” as used herein refers to a step in the synthesis ofan oligonucleotide wherein the newly synthesized phosphite bond isconverted into phosphate bond. If the desired internucleotide linkage isphosphorothioate, the term “oxidation” also refers to the addition of asulfur atom for the synthesis of a phosphorothioate linkage.

The term “capping” as used herein refers to a step in the synthesis ofan oligonucleotide wherein a chemical moiety is covalently attached toany free or unreacted hydroxyl groups on the support bound spacer,nucleic acid or oligonucleotide. The capping step is used to prevent theformation of undesired products, for example sequences of shorter lengththan the desired sequence resulting from subsequent coupling reactions.In a non-limiting example, acetic anhydride can be utilized to cap thespacer, nucleic acid, or oligonucleotide with an acetyl group. This stepcan also be preformed prior to the oxidation of the phosphite bondrather than after oxidation.

The term “activator” as used herein refers to a compound that is used togenerate a reactive phosphorus species, typically by displacing a lessreactive group on a trivalent phosphorus atom. Example of activatorsinclude but are not limited to tetrazole, S-ethyl tetrazole (SET),dicyanoimidazole (DCI), or 1-(mesitylsulfonyl)-3-nitro-1,2,4-1H-triazole(MSNT).

The term “5′-activated phosphorus species” as used herein refers to areactive phosphorus containing compound or phosphine, for example anucleotide 5′-O-phosphoramidite, H-phosphonate, phosphotriester,pyrophosphate, triphosphate, or phosphate that is further activated viadisplacement of a chemical group from the phosphorus atom with a morereactive chemical group.

The term “phosphine” or “phosphite” as used herein refers to a trivalentphosphorus species, for example compounds having Formula XIV:

wherein R can include the groups:

and wherein S and T independently include the groups:

The term “pyrophosphate” as used herein refers to a cyclic phosphatespecies comprising three phosphorus atoms.

The term “triphosphate” as used herein refers to a linear phosphatespecies comprising three phosphorus atoms. Nucleoside triphosphate canbe coupled via enzymatic activity, for example polymerase activity.

The term “H-phosphonate” as used herein refers to a pentavalentphosphorus with at least one hydrogen substituent.

The term “phosphate” as used herein refers to a pentavalent phosphorusspecies, for example a compound having Formula XV:

wherein R includes the groups:

and wherein S and T each independently can be a sulfur or oxygen atom ora group which can include:

and wherein M comprises a sulfur or oxygen atom. The phosphate of theinvention can comprise a nucleotide phosphate, wherein any R, S, or T inFormula XV comprises a linkage to a nucleic acid or nucleoside.

The term “phosphotriester” as used herein, refers to a trivalentphosphorus bearing three bonds to oxygen atoms

The term “in situ” as used herein refers to the generation of aparticular compound or reactive intermediate, for example aphosphoramidite of the invention, without purification and/or isolation.

The term “spacer” or “X” of Formula IX as used herein refers to a lineardi-radical chemical moiety that links the solid support with theterminal chemical group “B” via another di-radical chemical moiety “W”.The spacer maintains a degree of distance between the solid support andthe oligonucleotide being synthesized. The spacer characteristics, suchas length and chemical composition, can play an important role in theefficiency of RNA synthesis. The spacer is of sufficient length to allowthe necessary reagents to access the oligoribonucleotide beingsynthesized. The spacer, is generally linked to a terminal chemicalgroup such as a dimethoxytrityl protected nucleic acid or abasicderivative via a chemical linkage “W”, for example a succinate linkageprior to the initiation of oligonucleotide synthesis. This linkage canbe performed as a separate step resulting in the isolation of compoundsof Formulae I, II, III, IV and IX, or can be formed as the first step inthe synthesis of an oligonucleotide, for example, via derivatization ofthe solid support directly on an oligonucleotide synthesizer.

The term “solid support” as used herein refers to the material that isused as a scaffold from which oligonucleotide synthesis is initiated. Anumber of different solid supports suitable for the synthesis ofoligonucleotides and methods for preparation are given by Pon, 1993,Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotidesand Analogs, Humana Press, which is incorporated herein by reference inits entirety.

The term “terminal chemical group” as used herein refers to a chemicalentity attached via a spacer molecule or linker to a solid support fromwhich an oligonucleotide can be synthesized. The terminal chemical groupcan comprise a terminal residue of the oligonucleotide being synthesizedafter the oligonucleotide is released from the solid support, forexample a nucleoside, nucleotide, abasic derivative, or other chemicalmoiety that can be present at the 5′ or 3′ terminus of anoligonucleotide. In this example, the terminal chemical group cancomprise a dimethoxytrityl (DMT) protected nucleoside succinate such as5′-O-DMT-3′-β-succinyl uridine, cytidine, thymidine, adenosine orguanosine with out nitrogen protecting groups or a non-nucleosidicsuccinate such as a 5′-O-succinyl-3-β-dimethoxytrity deoxyribosederivative, where the succinyl portion of the terminal group is notpresent in the oligonucleotide after cleavage from the solid support. Anoxylate derivative can be used in place of succinate derivativescontemplated by the invention. Alternately, the terminal chemical groupcan comprise a structure that is not present in the oligonucleotideafter the oligonucleotide is released from the solid support, such ashydroquinone-O—O′-diacetic acid. A terminal chemical group derivatizedto a solid support via a spacer or linker molecule that is not presentin the oligonucleotide after the oligonucleotide is released from thesolid support can be used as a universal scaffold for oligonucleotidesynthesis since the composition of the oligonucleotide does not dependon the composition of the terminal chemical group, see for example Ponet al., 1999, Nucleic Acids Research, 27, 1531-1538).

The term “silanization” as used herein refers to the process ofintroducing a silyl, or silicon containing, group, for example to nativeglass. Silyl groups include, but are not limited to silyl ethers,alkylated silyl derivatives, or other substituted silyl groups.

The term “5′-hydroxyl protecting group compatible with oligonucleotidesynthesis” or “acid labile protecting moiety” refers to a protectinggroup, such as the dimethoxytrityl, monomethoxytrityl, and/or tritylgroups or other protecting groups, that can be used in a solid phase orsolution phase oligonucleotide synthesis.

The term “phosphoramidite” as used herein refers to a nitrogencontaining trivalent phosphorus derivative, for example, a2-cyanoethyl-N,N-diisopropylphosphoramidite.

The term “alkyl” as used herein refers to a saturated aliphatichydrocarbon, including straight-chain, branched-chain “isoalkyl”, andcyclic alkyl groups. The term “alkyl” also comprises alkoxy, alkyl-thio,alkyl-thio-alkyl, alkoxyalkyl, alkylamino, alkenyl, alkynyl, alkoxy,cycloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,C1-C6 hydrocarbyl, aryl or substituted aryl groups. Preferably, thealkyl group has 1 to 12 carbons. More preferably it is a lower alkyl offrom 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group canbe substituted or unsubstituted. When substituted, the substitutedgroup(s) preferably comprise hydroxy, oxy, thio, amino, nitro, cyano,alkoxy, alkyl-thio, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, silyl,alkenyl, alkynyl, alkoxy, cycloalkenyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, C1-C6 hydrocarbyl, aryl or substitutedaryl groups. The term “alkyl” also includes alkenyl groups containing atleast one carbon-carbon double bond, including straight-chain,branched-chain, and cyclic groups. Preferably, the alkenyl group has 2to 12 carbons. More preferably. it is a lower alkenyl of from 2 to 7carbons, even more preferably 2 to 4 carbons. The alkenyl group can besubstituted or unsubstituted. When substituted, the substituted group(s)preferably comprise hydroxy, oxy, thio, amino, nitro, cyano, alkoxy,alkyl-thio, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, silyl, alkenyl,alkynyl, alkoxy, cycloalkenyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, C1-C6 hydrocarbyl, aryl or substitutedaryl groups. The term “alkyl” also includes alkynyl groups containing atleast one carbon-carbon triple bond, including straight-chain,branched-chain, and cyclic groups. Preferably, the alkynyl group has 2to 12 carbons. More preferably it is a lower alkynyl of from 2 to 7carbons, more preferably 2 to 4 carbons. The alkynyl group can besubstituted or unsubstituted. When substituted, the substituted group(s)preferably comprise hydroxy, oxy, thio, amino, nitro, cyano, alkoxy,alkyl-thio, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, silyl, alkenyl,alkynyl, alkoxy, cycloalkenyl, cycloalkyl, cycloalkylalkyl,heterocycloalkyl, heteroaryl, C1-C6 hydrocarbyl, aryl or substitutedaryl groups. Alkyl groups or moieties of the invention can also includearyl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and estergroups. The preferred substituent(s) of aryl groups are halogen,trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl,and amino groups. An “alkylaryl” group refers to an alkyl group (asdescribed above) covalently joined to an aryl group (as describedabove). Carbocyclic aryl groups are groups wherein the ring atoms on thearomatic ring are all carbon atoms. The carbon atoms are optionallysubstituted. Heterocyclic aryl groups are groups having from 1 to 3heteroatoms as ring atoms in the aromatic ring and the remainder of thering atoms are carbon atoms. Suitable heteroatoms include oxygen,sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl,N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like,all optionally substituted. An “amide” refers to an —C(O)—NH—R, where Ris either alkyl, aryl, alkylaryl or hydrogen. An “ester” refers to an—C(O)—OR', where R is either alkyl, aryl, alkylaryl or hydrogen. It isunderstood that, for convenience, the above-mentioned groups can all beincluded within the definition of “alkyl” for purposes of thisapplication.

The term “alkanoyl” as used herein refers to an alkyl group attached tothe parent molecular moiety through a carbonyl group.

The term “alkoxyalkyl” as used herein refers to an alkyl-O-alkyl ether,for example methoxyethyl or ethoxymethyl.

The term “alkyl-thio-alkyl” as used herein refers to an alkyl-5-alkylthioether, for example methylthiomethyl or methylthioethyl.

The term “amino” as used herein refers to a nitrogen containing group asis known in the art derived from ammonia by the replacement of one ormore hydrogen radicals by organic radicals. For example, the terms“aminoacyl” and “aminoalkyl” refer to specific N-substituted organicradicals with acyl and alkyl substituent groups respectively.

The term “silylating reagent” as used herein refers to a chemicalreagent used to introduce a silyl group to a compound.

The term “alkenyl” as used herein refers to a straight or branchedhydrocarbon of a designed number of carbon atoms containing at least onecarbon-carbon double bond. Examples of “alkenyl” include vinyl, allyl,and 2-methyl-3-heptene.

The term “alkoxy” as used herein refers to an alkyl group of indicatednumber of carbon atoms attached to the parent molecular moiety throughan oxygen bridge. Examples of alkoxy groups include, for example,methoxy, ethoxy, propoxy and isopropoxy.

The term “alkynyl” as used herein refers to a straight or branchedhydrocarbon of a designed number of carbon atoms containing at least onecarbon-carbon triple bond. Examples of “alkynyl” include propargyl,propyne, and 3-hexyne.

The term “aryl” as used herein refers to an aromatic hydrocarbon ringsystem containing at least one aromatic ring. The aromatic ring canoptionally be fused or otherwise attached to other aromatic hydrocarbonrings or non-aromatic hydrocarbon rings. Examples of aryl groupsinclude, for example, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthaleneand biphenyl. Preferred examples of aryl groups include phenyl andnaphthyl.

The term “cycloalkenyl” as used herein refers to a C3-C8 cyclichydrocarbon containing at least one carbon-carbon double bond. Examplesof cycloalkenyl include cyclopropenyl, cyclobutenyl, cyclopentenyl,cyclopentadiene, cyclohexenyl, 1,3-cyclohexadiene, cycloheptenyl,cycloheptatrienyl, and cyclooctenyl.

The term “cycloalkyl” as used herein refers to a C3-C8 cyclichydrocarbon. Examples of cycloalkyl include cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

The term “cycloalkylalkyl,” as used herein, refers to a C3-C7 cycloalkylgroup attached to the parent molecular moiety through an alkyl group, asdefined above. Examples of cycloalkylalkyl groups includecyclopropylmethyl and cyclopentylethyl.

The terms “halogen” or “halo” as used herein refers to indicatefluorine, chlorine, bromine, and iodine.

The term “heterocycloalkyl,” as used herein refers to a non-aromaticring system containing at least one heteroatom selected from nitrogen,oxygen, and sulfur. The heterocycloalkyl ring can be optionally fused toor otherwise attached to other heterocycloalkyl rings and/ornon-aromatic hydrocarbon rings. Preferred heterocycloalkyl groups havefrom 3 to 7 members. Examples of heterocycloalkyl groups include, forexample, piperazine, morpholine, piperidine, tetrahydrofuran,pyrrolidine, and pyrazole. Preferred heterocycloalkyl groups includepiperidinyl, piperazinyl, morpholinyl, and pyrrolidinyl.

The term “heteroaryl” as used herein refers to an aromatic ring systemcontaining at least one heteroatom selected from nitrogen, oxygen, andsulfur. The heteroaryl ring can be fused or otherwise attached to one ormore heteroaryl rings, aromatic or non-aromatic hydrocarbon rings orheterocycloalkyl rings. Examples of heteroaryl groups include, forexample, pyridine, furan, thiophene, 5,6,7,8-tetrahydroisoquinoline andpyrimidine. Preferred examples of heteroaryl groups include thienyl,benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl,benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl,isoxazolyl, oxadiazolyl, isothiazolyl, benzisothiazolyl, triazolyl,tetrazolyl, pyrrolyl, indolyl, pyrazolyl, and benzopyrazolyl.

The term “C1-C6 hydrocarbyl” as used herein refers to straight,branched, or cyclic alkyl groups having 1-6 carbon atoms, optionallycontaining one or more carbon-carbon double or triple bonds. Examples ofhydrocarbyl groups include, for example, methyl, ethyl, propyl,isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl,neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, vinyl, 2-pentene,cyclopropylmethyl, cyclopropyl, cyclohexylmethyl, cyclohexyl andpropargyl. When reference is made herein to C1-C6 hydrocarbyl containingone or two double or triple bonds it is understood that at least twocarbons are present in the alkyl for one double or triple bond, and atleast four carbons for two double or triple bonds.

The term “nitrogen protecting group,” as used herein, refers to groupsknown in the art that are readily introduced on to and removed from anitrogen. Examples of nitrogen protecting groups include Boc, Cbz,benzoyl, and benzyl. See also “Protective Groups in Organic Synthesis”,3rd Ed., Greene, T. W. and related publications.

The term “5′-protected nucleoside” as used herein refers to a nucleosidebearing a 5′-protecting group, for example an acid labile protectinggroup such as a trityl, dimethoxytrityl, or monomethoxytrityl group.

The term “5′-protected N-protected nucleoside” as used herein refers toa 5′-protected nucleoside further comprising amino protection, forexample exocylic amine protection such as acyl or amide protection or2′-amino protection such as TFA or phthalimide protection.

The term “nucleotide” as used herein, refers to a heterocyclicnitrogenous base in N-glycosidic linkage with a phosphorylated sugar.Nucleotides are recognized in the art to include natural bases(standard), and modified bases well known in the art. Such bases aregenerally located at the 1′ position of a nucleotide sugar moiety.Nucleotides generally comprise a base, sugar and a phosphate group. Thenucleotides can be unmodified or modified at the sugar, phosphate and/orbase moiety, (also referred to interchangeably as nucleotide analogs,modified nucleotides, non-natural nucleotides, non-standard nucleotidesand other; see for example, Usman and McSwiggen, supra; Eckstein et al.,International PCT Publication No. WO 92/07065; Usman et al.,International PCT Publication No. WO 93/15187; Uhlman & Peyman, supraall are hereby incorporated by reference herein). There are severalexamples of modified nucleic acid bases known in the art as summarizedby Limbach et al., 1994, Nucleic Acids Res. 22, 2183. Some of thenon-limiting examples of chemically modified and other natural nucleicacid bases that can be introduced into nucleic acids include, inosine,purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil,2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl,aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines(e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne,quesosine, 2-thiouridine, 4-thiouridine, wybutosine, wybutoxosine,4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine,5′-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluridine, beta-D-galactosylqueosine,1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine,3-methylcytidine, 2-methyladenosine, 2-methylguanosine,N6-methyladenosine, 7-methylguanosine,5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine,5-methylcarbonylmethyluridine, 5-methyloxyuridine,5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine,beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine,threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35,14090; Uhlman & Peyman, supra). By “modified bases” in this aspect ismeant nucleotide bases other than adenine, guanine, cytosine and uracilat 1′ position or their equivalents; such bases can be used at anyposition, for example, within the catalytic core of an enzymatic nucleicacid molecule and/or in the substrate-binding regions of the nucleicacid molecule.

The term “nucleoside” as used herein, refers to a heterocyclicnitrogenous base in N-glycosidic linkage with a sugar. Nucleosides arerecognized in the art to include natural bases (standard), and modifiedbases well known in the art. Such bases are generally located at the 1′position of a nucleoside sugar moiety. Nucleosides generally comprise abase and sugar group. The nucleosides can be unmodified or modified atthe sugar, and/or base moiety, (also referred to interchangeably asnucleoside analogs, modified nucleosides, non-natural nucleosides,non-standard nucleosides and other; see for example, Usman andMcSwiggen, supra; Eckstein et al., International PCT Publication No. WO92/07065; Usman et al., International PCT Publication No. WO 93/15187;Uhlman & Peyman, supra all are hereby incorporated by reference herein).There are several examples of modified nucleic acid bases known in theart as summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183.Some of the non-limiting examples of chemically modified and othernatural nucleic acid bases that can be introduced into nucleic acidsinclude, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl,pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine,naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine),5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g.,5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g.6-methyluridine), propyne, quesosine, 2-thiouridine, 4-thiouridine,wybutosine, wybutoxosine, 4-acetylcytidine,5-(carboxyhydroxymethyl)uridine,5′-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluridine, beta-D-galactosylqueosine,1-methyladenosine, 1-methylinosine, 2,2-dimethylguanosine,3-methylcytidine, 2-methyladenosine, 2-methylguanosine,N6-methyladenosine, 7-methylguanosine,5-methoxyaminomethyl-2-thiouridine, 5-methylaminomethyluridine,5-methylcarbonylmethyluridine, 5-methyloxyuridine,5-methyl-2-thiouridine, 2-methylthio-N6-isopentenyladenosine,beta-D-mannosylqueosine, uridine-5-oxyacetic acid, 2-thiocytidine,threonine derivatives and others (Burgin et al., 1996, Biochemistry, 35,14090; Uhlman & Peyman, supra). By “modified bases” in this aspect ismeant nucleoside bases other than adenine, guanine, cytosine and uracilat 1′ position or their equivalents; such bases can be used at anyposition, for example, within the catalytic core of an enzymatic nucleicacid molecule and/or in the substrate-binding regions of the nucleicacid molecule.

The term “abasic” as used herein, refers to sugar moieties lacking abase or having other chemical groups in place of a base at the 1′position, (for more details see Wincott et al., International PCTpublication No. WO 97/26270).

The term “unmodified nucleoside” as used herein, refers to one of thebases adenine, cytosine, guanine, thymine, uracil joined to the 1′carbon of β-D-ribo-furanose.

The term “modified nucleoside” as used herein, refers to any nucleotidebase which contains a modification in the chemical structure of anunmodified nucleotide base, sugar and/or phosphate.

The term “oligonucleotide” as used herein, refers to a moleculecomprising two or more nucleotides. An oligonucleotide can compriseribonucleic acids, deoxyribonucleic acids, and combinations and/orchemically modified derivatives thereof. Oligonucleotides can comprisenucleic acids such as enzymatic nucleic acids, antisense nucleic acids,aptamers, decoys, allozymes, ssRNA, double stranded RNA, siRNA, triplexoligonucleotides or 2,5-A chimeras.

The term “enzymatic nucleic acid molecule” as used herein refers to anucleic acid molecule which has complementarity in a substrate bindingregion to a specified gene target, and also has an enzymatic activitywhich is active to specifically cleave target RNA. That is, theenzymatic nucleic acid molecule is able to intermolecularly cleave RNAand thereby inactivate a target RNA molecule. These complementaryregions allow sufficient hybridization of the enzymatic nucleic acidmolecule to the target RNA and thus permit cleavage. One hundred percentcomplementarity is preferred, but complementarity as low as 50-75% canalso be useful in this invention (see for example Werner and Uhlenbeck,1995, Nucleic Acids Research, 23, 2092-2096; Hammann et al., 1999,Antisense and Nucleic Acid Drug Dev., 9, 25-31). The nucleic acids canbe modified at the base, sugar, and/or phosphate groups. The termenzymatic nucleic acid is used interchangeably with phrases such asribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme oraptamer-binding ribozyme, regulatable ribozyme, catalyticoligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease,endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of theseterminologies describe nucleic acid molecules with enzymatic activity.The specific enzymatic nucleic acid molecules described in the instantapplication are not limiting in the invention and those skilled in theart will recognize that all that is important in an enzymatic nucleicacid molecule of this invention is that it has a specific substratebinding site which is complementary to one or more of the target nucleicacid regions, and that it have nucleotide sequences within orsurrounding that substrate binding site which impart a nucleic acidcleaving and/or ligation activity to the molecule (Cech et al., U.S.Pat. No. 4,987,071; Cech et al., 1988, 260 JAMA 3030).

The term “antisense nucleic acid”, as used herein refers to anon-enzymatic nucleic acid molecule that binds to target RNA by means ofRNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993Nature 365, 566) interactions and alters the activity of the target RNA(for a review, see Stein and Cheng, 1993 Science 261, 1004 and Woolf etal., U.S. Pat. No. 5,849,902). Typically, antisense molecules arecomplementary to a target sequence along a single contiguous sequence ofthe antisense molecule. However, in certain embodiments, an antisensemolecule can bind to a substrate such that the substrate molecule formsa loop, and/or an antisense molecule can bind such that the antisensemolecule forms a loop. Thus, the antisense molecule can be complementaryto two (or even more) non-contiguous substrate sequences or two (or evenmore) non-contiguous sequence portions of an antisense molecule can becomplementary to a target sequence or both. For a review of currentantisense strategies, see Schmajuk et al., 1999, J. Biol. Chem., 274,21783-21789, Delihas et al., 1997, Nature, 15, 751-753, Stein et al.,1997, Antisense N. A. Drug Dev., 7, 151, Crooke, 2000, Methods Enzymol.,313, 3-45; Crooke, 1998, Biotech. Genet. Eng. Rev., 15, 121-157, Crooke,1997, Ad. Pharmacol., 40, 1-49. In addition, antisense DNA can be usedto target RNA by means of DNA-RNA interactions, thereby activating RNaseH, which digests the target RNA in the duplex. The antisenseoligonucleotides can comprise one or more RNAse H activating region,which is capable of activating RNAse H cleavage of a target RNA.Antisense DNA can be synthesized chemically or expressed via the use ofa single stranded DNA expression vector or equivalent thereof.

The term “RNase H activating region” as used herein refers to a region(generally greater than or equal to 4-25 nucleotides in length,preferably from 5-11 nucleotides in length) of a nucleic acid moleculecapable of binding to a target RNA to form a non-covalent complex thatis recognized by cellular RNase H enzyme (see for example Arrow et al.,U.S. Pat. No. 5,849,902; Arrow et al., U.S. Pat. No. 5,989,912). AnRNase H enzyme binds to a nucleic acid molecule-target RNA complex andcleaves the target RNA sequence. An RNase H activating region comprises,for example, phosphodiester, phosphorothioate (preferably at least fourof the nucleotides are phosphorothiote substitutions; more specifically,4-11 of the nucleotides are phosphorothiote substitutions);phosphorodithioate, 5′-thiophosphate, or methylphosphonate backbonechemistry or a combination thereof. In addition to one or more backbonechemistries described above, an RNase H activating region can alsocomprise a variety of sugar chemistries. For example, an RNase Hactivating region can comprise deoxyribose, arabino, fluoroarabino or acombination thereof, nucleotide sugar chemistry. Those skilled in theart will recognize that the foregoing are non-limiting examples and thatany combination of phosphate, sugar and base chemistry of a nucleic acidthat supports the activity of RNase H enzyme is within the scope of thedefinition of an RNase H activating region and the instant invention.

The term “single stranded RNA” (ssRNA) as used herein refers to anaturally occurring or synthetic ribonucleic acid molecule comprising alinear single strand, for example a ssRNA can be a messenger RNA (mRNA),transfer RNA (tRNA), ribosomal RNA (rRNA) etc. of a gene.

The term “double stranded RNA” or “dsRNA” as used herein refers to adouble stranded RNA molecule capable of RNA interference, includingshort interfering RNA (siRNA), see for example Bass, 2001, Nature, 411,428-429; Elbashir et al., 2001, Nature, 411, 494-498)

The term “allozyme” as used herein refers to an allosteric enzymaticnucleic acid molecule, see for example see for example George et al.,U.S. Pat. Nos. 5,834,186 and 5,741,679, Shih et al., U.S. Pat. No.5,589,332, Nathan et al., U.S. Pat. No. 5,871,914, Nathan and Ellington,International PCT publication No. WO 00/24931, Breaker et al.,International PCT Publication Nos. WO 00/26226 and 98/27104, andSullenger et al., International PCT publication No. WO 99/29842.

The term “2-5A chimera” as used herein refers to an oligonucleotidecontaining a 5′-phosphorylated 2′-5′-linked adenylate residue. Thesechimeras bind to target RNA in a sequence-specific manner and activate acellular 2-5A-dependent ribonuclease which, in turn, cleaves the targetRNA (Torrence et al., 1993 Proc. Natl. Acad. Sci. USA 90, 1300;Silverman et al., 2000, Methods Enzymol., 313, 522-533; Player andTorrence, 1998, Pharmacol. Ther., 78, 55-113).

The term “triplex forming oligonucleotides” as used herein refers to anoligonucleotide that can bind to a double-stranded DNA in asequence-specific manner to form a triple-strand helix. Formation ofsuch triple helix structure has been shown to inhibit transcription ofthe targeted gene (Duval-Valentin et al., 1992 Proc. Natl. Acad. Sci.USA 89, 504; Fox, 2000, Curr. Med. Chem., 7, 17-37; Praseuth et. al.,2000, Biochim. Biophys. Acta, 1489, 181-206).

The term “decoy” as used herein refers to a nucleic acid molecule, forexample RNA or DNA, or aptamer that is designed to preferentially bindto a predetermined ligand. Such binding can result in the inhibition oractivation of a target molecule. A decoy or aptamer can compete with anaturally occurring binding target for the binding of a specific ligand.For example, it has been shown that over-expression of HIVtrans-activation response (TAR) RNA can act as a “decoy” and efficientlybinds HIV tat protein, thereby preventing it from binding to TARsequences encoded in the HIV RNA (Sullenger et al., 1990, Cell, 63,601-608). This is but a specific example and those in the art willrecognize that other embodiments can be readily generated usingtechniques generally known in the art, see for example Gold et al.,1995, Annu. Rev. Biochem., 64, 763; Brody and Gold, 2000, J.Biotechnol., 74, 5; Sun, 2000, Curr. Opin. Mol. Ther., 2, 100; Kusser,2000, J. Biotechnol., 74, 27; Hermann and Patel, 2000, Science, 287,820; and Jayasena, 1999, Clinical Chemistry, 45, 1628. Similarly, adecoy can be designed to bind to other proteins and block the binding ofDNA or RNA to a nucleic acid binding protein, or a decoy can be designedto bind to proteins and prevent other molecular interactions with theprotein.

Katzhendler et al., 1989, supra, also suggest that the optimal loadingof 3′-terminal chemical groups onto the spacer molecules should rangefrom 5-23.7 μmol per gram of solid support to achieve efficient DNAsynthesis.

Applicant has surprisingly found that the loading of greater than 40μmol of the 3′-terminal chemical group onto the spacer molecule, pergram of solid support allows for the efficient synthesis ofoligonucleotides, including RNA oligonucleotides. Thus, in a oneembodiment, this invention features the method for solid phase synthesisof oligonucleotides described in method A, wherein the terminal chemicalgroup is loaded onto the solid support bound spacer molecule at aconcentration greater than or equal to 40 μmol/gram of solid support andless than 100 μmol/gram, preferably 40, 45, 50, 55, 60, 65, 70, 75, 80,90, and 100 μmol/gram of solid support.

The term “loading” as used herein, refers to the covalent attachment ofa terminal chemical group, such as abasic succinate or another suitablechemical moiety onto the spacer molecule linked to the solid support.The terminal chemical group is either a protected initial nucleoside orany other chemical group that is attached at the 3′ end of theoligonucleotide being synthesized. Loading generally occurs prior to theinitiation of oligonucleotide synthesis.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The drawings will first briefly be described.

Drawings:

FIG. 1 is a schematic representation of a process for synthesis ofoligonucleotides using solid phase phosphoramidite chemistry. Theprocess includes detritylation (A), coupling (B), oxidation (C), andcapping (D), which are repeated until the oligonucleotide molecule iscompletely synthesized.

FIG. 2 displays examples of the spacers that can be used for thesynthesis of oligonucleotides. In addition, product yields and reactionefficiencies for the synthesis of oligonucleotides are also included.

FIG. 3 shows an HPLC chromatograph of ribozyme synthesized using CPGlinked HHDA spacer. The reaction was performed using controlled poreglass with loading of 56 μmol/g of abasic succinate and yielded 266optical density units (ODU)/μmol of crude material.

FIG. 4 is shows the HPLC chromatographs of ribozymes synthesized onCPG-linker PEG and UDDA Spacers.

FIG. 5 is a non-limiting example of a chemical scheme for the synthesisof derivatized 22 atom CPG, HHDA spacer.

FIG. 6 is a non-limiting example of a chemical scheme for the synthesisof derivatized 19 atom CPG, PEG-CPG spacer.

FIG. 7 is a non-limiting example of a chemical scheme for the synthesisof derivatized 20 atom CPG, UDDA spacer.

FIG. 8 displays examples of general formulas covered under the presentinvention. In formula a, X is an integer greater than or equal to 2 andless than or equal to 6. In formula b, Y is an integer greater than orequal to 1 and less than or equal to 4. In formula c, V is an integergreater than or equal to 5 and less than or equal to 16. In all of theformulae a-d, SP represents a solid support; where the solid support isselect from a group including controlled pore glass; polystyrene; silicagel; cellulose paper; polyamide/kieselgur; and polacryloylmorpholide; Brepresents the terminal chemical group such as abasic succinate,nucleotides, etc., where B can be linked to the growing RNA chain via3′-5′, 3′-2′, or 3′-3′ linkages; and R is independently a moietyselected from a group consisting of alkyl, alkenyl, alkynyl, aryl,alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester.

FIG. 9 is a non-limiting example of a chemical scheme for the synthesisof derivatized 13 atom CPG, C9 spacer.

FIG. 10 shows a capillary gel electrophoresis (CGE) chromatogram of acrude 36-mer enzymatic nucleic acid synthesized on 13 atom CPG, C9spacer with an inverted abasic terminal moiety.

FIG. 11 is a schematic representation of a process for synthesis ofoligonucleotides using solid phase phosphoramidite chemistry. Theprocess includes detritylation (A), 5′-activation (B), coupling (C),oxidation (D), and capping (E), which are repeated until theoligonucleotide molecule is completely synthesized.

OLIGONUCLEOTIDE SYNTHESIS

In one embodiment, the invention features a method (Method E) for thesynthesis of oligonucleotides comprising: 5′-deblocking, 5′-activation,coupling, oxidation, and capping, wherein these steps are repeated underconditions suitable for the synthesis of an oligonucleotide, and wherein5′-activation comprises the in situ formation of an activated5′-phosphorus species and coupling comprises the nucleophilic attack ofthe activated 5′-phosphorus species under conditions suitable forcovalent attachment of the nucleophile to the activated 5′-phosphorusspecies.

In another embodiment, the 5′-activation contemplated by the inventioncomprises the in situ formation of a nucleoside 5′-O-phosphoramidite. Inyet another embodiment, the nucleoside 5′-O-phosphoramidite of theinvention is 5′-O-nucleoside2-cyanoethyl-N,N-diisopropylphosphoramidite.

In one embodiment, the 5′-activation contemplated by the inventioncomprises conjugation of a nucleoside 5′-hydroxyl with a phosphine inthe presence of an activator. In another embodiment, the phosphinecontemplated by the invention comprisescyanoethyl-(bis)-N,N-diisopropylphosphoramidite (2-cyanoethyltetraisopropylphosphorodiamidite) and the activator comprises S-ethyltetrazole (SET), tetrazole, or dicyanoimidazole (DCI).

In another embodiment, the method for the synthesis of oligonucleotidescomprising: 5′-deblocking, 5′-activation, coupling, oxidation, andcapping is a solid phase synthesis, solution phase synthesis, or mixedphase synthesis.

In yet another embodiment, solid phase synthesis via Method A of theinvention is carried out on a solid support comprising silicon-basedchips, controlled pore glass; polystyrene; nylon, silica gel; cellulosepaper; polyamide/kieselgur; or polacryloylmorpholide.

In one embodiment, the conditions suitable for covalent attachment ofthe nucleophile to the activated 5′-phosphorus species in Method A ofthe invention comprises the use of an activator, or example S-ethyltetrazole (SET), tetrazole, or dicyanoimidazole (DCI), in the presenceof a 5′-protected or 5′-protected N-protected nucleoside bearing anucleophile such as a hydroxyl group.

The compounds and methods of the invention are readily adapted for usewith known synthetic protocols for oligonucleotide synthesis. Inaddition, the compounds and methods of the invention can be used tosynthesize both naturally occurring and chemically modified nucleic acidpolymers.

The method of oligonucleotide synthesis generally followed in the art isdescribed by Usman et al., supra, Scaringe et al., Nucleic Acids Res.1990, 18, 5433-5441, and Caruthers, U.S. Pat. No. 4,458,066, and makesuse of common nucleic acid protecting and coupling groups, such asdimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end.Alternately, Method E of the invention is used, wherein an activatedphosphorus species is generated in situ before coupling with theincoming nucleoside. Those skilled in the art will recognize that otherprotecting and coupling groups can be used for solid phaseoligonucleotide synthesis and are hence within the scope of theinvention. A more detailed description of oligonucleotide synthesisfollows.

Solid support and spacer selection: Prior to the initiation ofoligonucleotide synthesis, a proper solid support and spacer isselected. A number of different inorganic polymers can be utilized forthe solid phase synthesis of oligonucleotides including silica,aluminosilicates, borosilicates, porous glass, metal oxides, and clays.The type of solid support is often chosen based on the length of theoligonucleotide to be synthesized. The support is preferably comprisedof a uniform surface with pores large enough to accommodate theoligonucleotide of interest (e.g. 300-2000 Å). Additional preferablecharacteristics of the support include particle size (40-500 mesh), bulkdensity (0.1-1.0 g/cc), SS. Area (10-200 M²/g), and pore volume (0.2-3.0cc/g). In a preferred embodiment, the solid support is comprised ofcontrolled pore glass (CPG) with a pore size of about 630 Å, a particlesize of about 120 to 200 mesh, a bulk density of about 0.24 g/cc, a SS.Area of about 77 M²/g, and a pore volume of about 1.8 cc/g. In addition,the support contains a minimum number of additional surface chemicalgroups that can react to produce undesired products and thus loweryield.

The molecular characteristics of the spacer are expected to have asignificant effect on the efficiency of oligonucleotide synthesis. Thesynthesis of oligonucleotides occurs in close proximity to the surfaceof the solid support and therefore, the length and type of spacer usedcan be a critical variable (Pon, supra). Contrary to the publishedliterature, applicant believes that the chemistry of the spacer can bemore important than the length of the spacer. A spacer with chemistrythat promotes the extension rather than contraction of the spacer chaincan have a greater probability of supporting efficient synthesis ofoligonucleotides. The quantity of initial nucleotide or chemical moietyloaded onto the solid support can also play a role in the efficiency ofoligonucleotide synthesis. Efficient synthesis of DNA oligonucleotideshas been reported at a loading of between 5.5-24 μmol spacer per gram ofsolid support (Katzhendler et al., supra). Applicant believes that forthe synthesis of oligonucleotides having RNA nucleotides, spacer loadingcan be increased to 40-100 μmol without a substantial decrease in theefficiency of oligonucleotide synthesis. Therefore, in one embodiment,the invention features a method for oligonucleotide synthesis where aderivatized solid support of the invention comprises a loading of 40-100μmol.

In another embodiment, the invention features the use of an inlinemixture upstream of the solid support used in a method of the invention.The inline mixer can allow for homogeneity of thephosphoramidite/activator solution prior to contact with the solidsupport, thereby resulting in complete phosphoramidite activation. Inthe absence of the inline mixer, the phosphoramidite/activator streamcan have localized areas of a highly concentrated species or “plugs”consisting of either phosphoramidite or activator. The sequentialexposure of the support to these “plugs” can result in the formation ofN+x oligomers (x being any integer greater than or equal to 1) and/orother side reactions. Most notably, concentrated “plugs” of activatorcan deblock acid labile protecting groups resulting in undesirablepolymerization events. Concentrated “plugs” of phosphoramidite lackingactivator can result in the effective lowering of reactive equivalents,thereby compromising synthesis quality (N−1 events). The use of inlinemixer is likely to improve the overall efficiency of oligonucleotidesynthesis, quality of oligonucleotides synthesized and/or the overallyield of the oligonucleotide synthesized.

The term “inline mixer” as used herein refers to any type of mixer thatis compatible with an oligonucleotide synthesis platform, provided thateffective mixing of the desired components involved in the synthesis isenabled. An inline (pipeline) mixer can comprise any of the followingtypes: Inline fixed element mixer, inline removable element mixer,inline edge sealed mixer, or inline high efficiency vortex mixer. In aspecific example, the use of a Komax Systems Inc. Inline tube mixer,part number 375-027 is provided.

Synthesis of Oligonucleotides (phosphite-triester method): The tritylgroup (e.g. dimethoxytrityl) is removed from the initial nucleotide ornon-nucleotide moiety (B in the above Formulae) on the spacer fromeither the 2′, 3′, or 5′ end (FIG. 1A). Removal of the trityl groupexposes a reactive hydroxyl group capable of binding to the nextnucleoside. The next nucleoside, in the form of a phosphoramiditemolecule is activated using reagents such as, but not limited to,tetrazole, S-ethyl tetrazole, and 4,5-dicyanoimidazole (DCI), and isattached to the initial nucleoside by an internucleotidephosphite-triester linkage (FIG. 1B). The phosphite-triester is thenoxidized to yield a phophate bond which is the more stableinternucleotide linkage (FIG. 1C).

Alternately, The trityl group (e.g. dimethoxytrityl) is removed from theinitial nucleotide or non-nucleotide moiety (B in the above Formulae) onthe spacer from either the 2′, 3′, or 5′ end (FIG. 11A). Removal of thetrityl group exposes a reactive hydroxyl group. The free hydroxyl isthen coupled to a phosphine in the presence of an activator such as, butnot limited to, tetrazole, S-ethyl tetrazole, and 4,5-dicyanoimidazole(DCI), to generate a reactive 5′-phosphorus species (FIG. 11B). The nextnucleoside, in the form of a 5′-protected molecule bearing a freenucleophile, for example a 3′-hydroxyl, is attached to the initialnucleoside by an internucleotide phosphite-triester linkage (FIG. 11C).The phosphite-triester is then oxidized to yield a phophate bond whichis the more stable internucleotide linkage (FIG. 11D)

Because the addition of activated phosphoramidites onto detritylatedhydroxyl groups or addition of nucleophiles to 5′-activated phosphorusspecies usually does not proceed to 100% completion, these unreactivehydroxyl groups are capped to prevent the formation of undesiredproducts. For example, acetic anhydride can be utilized to cap thespacer with an acetyl group (FIG. 1D). This capping step can optionallytake place before or after the oxidation of the phosphite bond.

The steps described above, from detritylation to capping, is repeateduntil all of the desired nucleosides are added onto the growingoligonucleotide chain. The newly synthesized nucleic acid molecule isthen ready for the removal of all existing protecting groups, forexample phosphate ester protecting groups such as cyanoethyl protectinggroups, base protecting groups such as acetyl, benzoyl and isobutyrylgroups, and protecting groups from the 2′ position of the nucleotides,such as tert-butyldimethylsilyl groups for ribonucleotides or phthaloylgroups for 2′-amino nucleosides.

In a non-limiting example, small scale synthesis of non-ribonucleotide(2′-OH) containing oligonucleotides are conducted on a 394 AppliedBiosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 2.5min coupling step for 2′-O-methylated nucleotides and a 45 sec couplingstep for 2′-deoxy nucleotides. Table I outlines the amounts and thecontact times of the reagents used in the synthesis cycle.Alternatively, syntheses at the 0.2 μmol scale can be performed on a96-well plate synthesizer, such as the instrument produced by Protogene(Palo Alto, Calif.) with minimal modification to the cycle. A 33-foldexcess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a105-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can beused in each coupling cycle of 2′-O-methyl residues relative topolymer-bound 5′-hydroxyl. A 22-fold excess (40 μL of 0.11 M=4.4 μmol)of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40μL of 0.25 M=10 μmol) can be used in each coupling cycle of deoxyresidues relative to polymer-bound 5′-hydroxyl. Average coupling yieldson the 394 Applied Biosystems, Inc. synthesizer, determined bycolorimetric quantitation of the trityl fractions, are typically97.5-99%. Other oligonucleotide synthesis reagents for the 394 AppliedBiosystems, Inc. synthesizer include; detritylation solution is 3% TCAin methylene chloride (ABI); capping is performed with 16% N-methylimidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF(ABI); and oxidation solution is 16.9 mM I₂, 49 mM pyridine, 9% water inTHF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile isused directly from the reagent bottle. S-Ethyl tetrazole solution (0.25M in acetonitrile) is made up from the solid obtained from AmericanInternational Chemical, Inc. Alternately, for the introduction ofphosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one1,1-dioxide, 0.05 M in acetonitrile) is used.

Deprotection of the oligonucleotide is performed as follows: thepolymer-bound trityl-on oligoribonucleotide is transferred to a 4 mLglass screw top vial and suspended in a solution of 40% aq. methylamine(1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatantis removed from the polymer support. The support is washed three timeswith 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is thenadded to the first supernatant. The combined supernatants, containingthe oligoribonucleotide, are dried to a white powder.

The method of synthesis used for oligonucleotides comprising RNAnucleotides (2′-OH) and/or chemically modified RNA nucleotides includingother modifications such as 2′-C-allyl nucleotides, 2′-amino nucleotidesor 2′-β-amino nucleotides follows the procedure as described in Usman etal., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al., 1990, NucleicAcids Res., 18, 5433; and Wincott et al., 1995, Nucleic Acids Res. 23,2677-2684 Wincott et al., 1997, Methods Mol. Bio., 74, 59, and makes useof common nucleic acid protecting and coupling groups, such asdimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In anon-limiting example, small scale syntheses are conducted on a 394Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocolwith a 7.5 min coupling step for alkylsilyl protected nucleotides and a2.5 min coupling step for 2′-O-methylated nucleotides. Table I outlinesthe amounts and the contact times of the reagents used in the synthesiscycle. Alternatively, syntheses at the 0.2 μmol scale can be done on a96-well plate synthesizer, such as the instrument produced by Protogene(Palo Alto, Calif.) with minimal modification to the cycle. A 33-foldexcess (60 μl of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can beused in each coupling cycle of 2′-O-methyl residues relative topolymer-bound 5′-hydroxyl. A 66-fold excess (120 μL of 0.11 M=13.2 μmol)of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess ofS-ethyl tetrazole (120 μL of 0.25 M=30 μmol) can be used in eachcoupling cycle of ribo residues relative to polymer-bound 5′-hydroxyl.Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer,determined by colorimetric quantitation of the trityl fractions, aretypically 97.5-99%. Other oligonucleotide synthesis reagents for the 394Applied Biosystems, Inc. synthesizer include; detritylation solution is3% TCA in methylene chloride (ABI); capping is performed with 16%N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10%2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I₂, 49 mMpyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson SynthesisGrade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solidobtained from American International Chemical, Inc. Alternately, for theintroduction of phosphorothioate linkages, Beaucage reagent(3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

Deprotection of the RNA containing oligonucleotides is performed usingeither a two-pot or one-pot protocol. For the two-pot protocol, thepolymer-bound trityl-on oligoribonucleotide is transferred to a 4 mLglass screw top vial and suspended in a solution of 40% aq. methylamine(1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatantis removed from the polymer support. The support is washed three timeswith 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is thenadded to the first supernatant. The combined supernatants, containingthe oligoribonucleotide, are dried to a white powder. The basedeprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMPsolution (300 μL of a solution of 1.5 mL N-methylpyrrolidinone, 750 μLTEA and 1 mL TEA.3HF to provide a 1.4 M HF concentration) and heated to65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH₄HCO₃.

Alternatively, for the one-pot protocol, the polymer-bound trityl-oholigoribonucleotide is transferred to a 4 mL glass screw top vial andsuspended in a solution of 33% ethanolic methylamine/DMSO:1/1 (0.8 mL)at 65° C. for 15 min. The vial is brought to r.t. TEA.3HF (0.1 mL) isadded and the vial is heated at 65° C. for 15 min. The sample is cooledat −20° C. and then quenched with 1.5 M NH₄HCO₃.

In another non-limiting example, small scale synthesis ofoligonucleotides are conducted on a 394 Applied Biosystems, Inc.synthesizer according to Method E of the invention using a 0.2 μmolscale protocol. A 2-10 minute activation time is used to couplecyanoethyl-(bis)-N,N-diisopropylethyl phosphoramidite (2-cyanoethyltetraisopropylphosphorodiamidite) (1.1-10 equivalents) to a freeterminal hydroxyl group in the presence of 1.1-10 equivalents of SET.This is followed by a 1-10 min coupling step for 5′-protectednucleotides in the presence of additional SET (1-10 equivalents). Theremainder of the synthesis cycle is performed according to the examplesabove.

Purification: The most quantitative procedure for recovering the fullydeprotected oligonucleotide is by either ethanol precipitation, or ananion exchange cartridge desalting, as described in Scaringe et al.Nucleic Acids Res. 1990, 18, 5433-5341. The purification of longoligonucleotide sequences can be accomplished by a two-stepchromatographic procedure in which the oligonucleotide is first purifiedon a reverse phase column with either the trityl group at the 5′position on or off. This purification is accomplished using anacetonitrile gradient with triethylammonium or bicarbonate salts as theaqueous phase. In the case of the trityl on purification, the tritylgroup can be removed by the addition of an acid and drying of thepartially purified oligonucleotide molecule. The final purification iscarried out on an anion exchange column, using alkali metal perchloratesalt gradients to elute the fully purified oligonucleotide molecule asthe appropriate metal salts, e.g. Na⁺, Li⁺ etc. A final de-salting stepon a small reverse-phase cartridge completes the purification procedure.

For purification of the trityl-on oligomers, the quenched NH₄HCO₃solution is loaded onto a C-18 containing cartridge that had beenprewashed with acetonitrile followed by 50 mM TEAA. After washing theloaded cartridge with water, the RNA is detritylated with 0.5% TFA for13 min. The cartridge is then washed again with water, salt exchangedwith 1 M NaCl and washed with water again. The oligonucleotide is theneluted with 30% acetonitrile.

Applications

The methods of the present invention can be employed to synthesizehighly pure samples of oligonucleotides which can be used for a numberof applications. A great deal of effort has been placed on blocking oraltering cellular processes such as transcription and translation for avariety of purposes, such as understanding biology, gene function,disease processes, and identifying novel therapeutic targets. Moleculescapable of blocking these processes include but are not limited toenzymatic nucleic acid molecule, antisense molecules, 2-5A chimeras,decoys, siRNA, triplex oligonucleotides, and allozymes as describedherein.

For example, enzymatic nucleic acid molecules can be synthesized whichcan inhibit gene expression in a highly specific manner by binding toand causing the cleavage of the mRNA corresponding to the gene ofinterest, and thereby prevent production of the gene product(Christoffersen, Nature Biotech, 1997, 2, 483-484).

By monitoring inhibition of gene expression and correlation withphenotypic results, the relative importance of the particular genesequence to disease pathology can be established. The process can beboth fast and highly selective, and allow for the process to be used atany point in the development of the organism.

Several varieties of naturally-occurring enzymatic RNAs are presentlyknown. In addition, several in vitro selection (evolution) strategies(Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolvenew nucleic acid catalysts capable of catalyzing cleavage and ligationof phosphodiester linkages (Joyce, 1989, Gene, 82, 83-87; Beaudry etal., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267,90-97; Breaker et al., 1994, TIBTECH 12, 268; Bartel et al., 1993,Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al.,1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 7, 442;Santoro et al., 1997, Proc. Natl. Acad. Sci., 94, 4262; Tang et al.,1997, RNA 3, 914; Nakamaye & Eckstein, 1994, supra; Long & Uhlenbeck,1994, supra; Ishizaka et al., 1995, supra; Vaish et al., 1997,Biochemistry 36, 6495; all of these are incorporated by referenceherein). Each can catalyze a series of reactions including thehydrolysis of phosphodiester bonds in trans (and thus can cleave otherRNA molecules) under physiological conditions. Nucleic acid molecules ofthis invention will block to some extent gene and protein expression andcan be used to treat disease or diagnose disease associated with thelevels of disease related genes and/or proteins.

The enzymatic nature of an enzymatic nucleic acid molecule can allow theconcentration of enzymatic nucleic acid molecule necessary to affect atherapeutic treatment to be lower than a nucleic acid molecule lackingenzymatic activity, such as an antisense nucleic acid. This reflects theability of the enzymatic nucleic acid molecule to act enzymatically.Thus, a single enzymatic nucleic acid molecule is able to cleave manymolecules of target RNA. In addition, the enzymatic nucleic acidmolecule is a highly specific inhibitor, with the specificity ofinhibition depending not only on the base-pairing mechanism of bindingto the target RNA, but also on the mechanism of target RNA cleavage.Single mismatches, or base-substitutions, near the site of cleavage canbe chosen to completely eliminate catalytic activity of a enzymaticnucleic acid molecule.

Nucleic acid molecules having an endonuclease enzymatic activity areable to repeatedly cleave other separate RNA molecules in a nucleotidebase sequence-specific manner. Such enzymatic nucleic acid molecules canbe targeted to virtually any RNA transcript, and achieve efficientcleavage in vitro (Zaug et al., 324, Nature 429 1986; Uhlenbeck, 1987Nature 328, 596; Kim et al., 84 Proc. Natl. Acad. Sci. USA 8788, 1987;Dreyfus, 1988, Einstein Quart. J. Bio. Med., 6, 92; Haseloff andGerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; and Jefferieset al., 17 Nucleic Acids Research 1371, 1989; Santoro et al., 1997supra).

Because of their sequence specificity, trans-cleaving enzymatic nucleicacid molecules can be used as therapeutic agents for human disease(Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294;Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymaticnucleic acid molecules can be designed to cleave specific RNA targetswithin the background of cellular RNA. Such a cleavage event renders theRNA non-functional and abrogates protein expression from that RNA. Inthis manner, synthesis of a protein associated with a disease state canbe selectively inhibited (Warashina et al., 1999, Chemistry and Biology,6, 237-250).

Enzymatic nucleic acid molecules of the invention that areallosterically regulated (“allozymes”) can be used to down-regulate geneexpression. These allosteric enzymatic nucleic acids or allozymes (seefor example George et al., U.S. Pat. Nos. 5,834,186 and 5,741,679, Shihet al., U.S. Pat. No. 5,589,332, Nathan et al., U.S. Pat. No. 5,871,914,Nathan and Ellington, International PCT publication No. WO 00/24931,Breaker et al., International PCT Publication Nos. WO 00/26226 and98/27104, and Sullenger et al., International PCT publication No. WO99/29842) are designed to respond to a signaling agent, for example, amutant protein, wild-type protein, mutant RNA, wild-type RNA, otherproteins and/or RNAs involved in a disease or infection, which in turnmodulates the activity of the enzymatic nucleic acid molecule. Inresponse to interaction with a predetermined signaling agent, theallosteric enzymatic nucleic acid molecule's activity is activated orinhibited such that the expression of a particular target is selectivelydown-regulated. In a specific example, allosteric enzymatic nucleic acidmolecules that are activated by interaction with a RNA encoding apathogenic protein are used as therapeutic agents in vivo. The presenceof RNA encoding the pathogenic protein activates the allostericenzymatic nucleic acid molecule that subsequently cleaves the RNAencoding the protein resulting in the inhibition of protein expression.In this manner, cells that express the pathogenic protein areselectively targeted.

In another non-limiting example, an allozyme can be activated by aprotein, peptide, or mutant polypeptide that caused the allozyme toinhibit the expression of a gene, by, for example, cleaving RNA encodedby the gene. In this non-limiting example, the allozyme acts as a decoyto inhibit the function of a protein and also inhibit the expression ofprotein once activated by the protein.

Antisense molecules can be modified or unmodified RNA, DNA, or mixedpolymer oligonucleotides and primarily function by specifically bindingto matching sequences resulting in inhibition of peptide synthesis(Woo-Pong, November 1994, BioPharm, 20-33). The antisenseoligonucleotide binds to target RNA by Watson Crick base-pairing andblocks gene expression by preventing ribosomal translation of the boundsequences either by steric blocking or by activating RNase H enzyme.Antisense molecules can also alter protein synthesis by interfering withRNA processing or transport from the nucleus into the cytoplasm(Mukhopadhyay & Roth, 1996, Crit. Rev. in Oncogenesis 7, 151-190).

In addition, binding of single stranded DNA to RNA can result innuclease degradation of the heteroduplex (Woo-Pong, supra; Crooke,supra). To date, the only backbone modified DNA chemistry which act assubstrates for RNase H are phosphorothioates, phosphorodithioates, andborontrifluoridates. Recently it has been reported that 2′-arabino and2′-fluoro arabino-containing oligos can also activate RNase H activity.

A number of antisense molecules have been described that utilize novelconfigurations of chemically modified nucleotides, secondary structure,and/or RNase H substrate domains (Woolf et al., International PCTPublication No. WO 98/13526; Thompson et al., International PCTPublication No. WO 99/54459; Hartmann et al., U.S. Ser. No. 60/101,174,filed on Sep. 21, 1998). All of these references are incorporated byreference herein in their entirety.

In addition, antisense deoxyoligoribonucleotides can be used to targetRNA by means of DNA-RNA interactions, thereby activating RNase H, whichdigests the target RNA in the duplex. Antisense DNA can be expressed viathe use of a single stranded DNA intracellular expression vector orequivalents and variations thereof.

Single stranded DNA can be designed to bind to genomic DNA in a sequencespecific manner. Triplex Forming Oligonucleotides (TFOs) are comprisedof pyrimidine-rich oligonucleotides which bind DNA helices throughHoogsteen Base-pairing. The resulting triple helix composed of the DNAsense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase.The TFO mechanism can result in gene expression or cell death sincebinding can be irreversible (Mukhopadhyay & Roth, supra).

The 2-5 A system is an interferon-mediated mechanism for RNA degradationfound in higher vertebrates (Mitra et al., 1996, Proc Nat Acad Sci USA93, 6780-6785). Two types of enzymes, 2-5A synthetase and RNase L, arerequired for RNA cleavage. The 2-5A synthetases require double strandedRNA to form 2′-5′ oligoadenylates (2-5A). 2-5A then acts as anallosteric effector for utilizing RNase L which has the ability tocleave single stranded RNA. The ability to form 2-5A structures withdouble stranded RNA makes this system particularly useful for inhibitionof viral replication.

(2′-5′) oligoadenylate structures can be covalently linked to antisensemolecules to form chimeric oligonucleotides capable of RNA cleavage(Torrence, supra). These molecules putatively bind and activate a 2-5Adependent RNase, the oligonucleotide/enzyme complex then binds to atarget RNA molecule which can then be cleaved by the RNase enzyme. Thecovalent attachment of 2′-5′ oligoadenylate structures is not limited toantisense applications, and can be further elaborated to includeattachment to nucleic acid molecules of the instant invention.

Targets for useful enzymatic nucleic acid molecules and antisensenucleic acids can be determined as disclosed in Draper et al., WO93/23569; Sullivan et al., WO 93/23057; Thompson et al., WO 94/02595;Draper et al., WO 95/04818; McSwiggen et al., U.S. Pat. No. 5,525,468,and hereby incorporated by reference herein in totality. Other examplesinclude the following PCT applications, which concern inactivation ofexpression of disease-related genes: WO 95/23225, WO 95/13380, WO94/02595, incorporated by reference herein. Rather than repeat theguidance provided in those documents here, provided below are specificexamples of such methods, not limiting to those in the art. Enzymaticnucleic acid molecules to such targets are designed as described inthose applications and synthesized to be tested in vitro and in vivo, asalso described. The sequences of human RNAs are screened for optimalenzymatic nucleic acid target sites using a computer-folding algorithm.While human sequences can be screened and enzymatic nucleic acidmolecule and/or antisense thereafter designed, as discussed inStinchcomb et al., WO 95/23225, mouse targeted enzymatic nucleic acidmolecules can be useful to test efficacy of action of the enzymaticnucleic acid molecule and/or antisense prior to testing in humans.

Optimizing Activity of the Nucleic Acid Molecule of the Invention.

Chemically synthesizing nucleic acid molecules with modifications (base,sugar and/or phosphate) that prevent their degradation by serumribonucleases can increase their potency (see e.g., Eckstein et al.,International Publication No. WO 92/07065; Perrault et al., 1990 Nature344, 565; Pieken et al., 1991, Science 253, 314; Usman and Cedergren,1992, Trends in Biochem. Sci. 17, 334; Usman et al., InternationalPublication No. WO 93/15187; and Rossi et al., International PublicationNo. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; and Burgin et al.,supra; all of these describe various chemical modifications that can bemade to the base, phosphate and/or sugar moieties of the nucleic acidmolecules herein). Modifications which enhance their efficacy in cells,and removal of bases from nucleic acid molecules to shortenoligonucleotide synthesis times and reduce chemical requirements aredesired. (All these publications are hereby incorporated by referenceherein).

There are several examples in the art describing sugar, base andphosphate modifications that can be introduced into nucleic acidmolecules with significant enhancement in their nuclease stability andefficacy. For example, oligonucleotides are modified to enhancestability and/or enhance biological activity by modification withnuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-fluoro,2′-O-methyl, 2′-H, nucleotide base modifications (for a review see Usmanand Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic AcidsSymp. Ser. 31, 163; Burgin et al., 1996, Biochemistry, 35, 14090). Sugarmodification of nucleic acid molecules have been extensively describedin the art (see Eckstein et al., International Publication PCT No. WO92/07065; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al.Science, 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem.Sci., 1992, 17, 334-339; Usman et al. International Publication PCT No.WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995,J. Biol. Chem., 270, 25702; Beigelman et al., International PCTpublication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824;Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCTPublication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082,404which was filed on Apr. 20, 1998; Karpeisky et al., 1998, TetrahedronLett., 39, 1131; Earnshaw and Gait, 1998, Biopolymers (Nucleic acidSciences), 48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67,99-134; and Burlina et al., 1997, Bioorg. Med. Chem., 5, 1999-2010; allof the references are hereby incorporated in their totality by referenceherein). Such publications describe general methods and strategies todetermine the location of incorporation of sugar, base and/or phosphatemodifications and the like into enzymatic nucleic acid molecules withoutinhibiting catalysis. In view of such teachings, similar modificationscan be used as described herein to modify the nucleic acid molecules ofthe instant invention.

While chemical modification of oligonucleotide internucleotide linkageswith phosphorothioate, phosphorothioate, and/or 5′-methylphosphonatelinkages improves stability, too many of these modifications can causesome toxicity. Therefore when designing nucleic acid molecules theamount of these internucleotide linkages should be minimized. Thereduction in the concentration of these linkages should lower toxicityresulting in increased efficacy and higher specificity of thesemolecules.

Nucleic acid molecules having chemical modifications that maintain orenhance activity are provided. Such nucleic acid molecules are alsogenerally more resistant to nucleases than unmodified nucleic acidmolecules. Thus, in a cell and/or in vivo the activity may not besignificantly lowered. Therapeutic nucleic acid molecules deliveredexogenously are optimally stable within cells until translation of thetarget RNA has been inhibited long enough to reduce the levels of theundesirable protein. This period of time varies between hours to daysdepending upon the disease state. Nucleic acid molecules are preferablyresistant to nucleases in order to function as effective intracellulartherapeutic agents. Improvements in the chemical synthesis of RNA andDNA (Wincott et al., 1995 Nucleic Acids Res. 23, 2677; Caruthers et al.,1992, Methods in Enzymology 211, 3-19 (incorporated by referenceherein)) have expanded the ability to modify nucleic acid molecules byintroducing nucleotide modifications to enhance their nuclease stabilityas described above.

Use of the nucleic acid-based molecules of the invention can lead tobetter treatment of the disease progression by affording the possibilityof combination therapies (e.g., multiple antisense or enzymatic nucleicacid molecules targeted to different genes, nucleic acid moleculescoupled with known small molecule inhibitors, or intermittent treatmentwith combinations of molecules (including different motifs) and/or otherchemical or biological molecules). The treatment of patients withnucleic acid molecules can also include combinations of different typesof nucleic acid molecules.

Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acidmolecules and antisense nucleic acid molecules) delivered exogenouslyare optimally stable within cells until translation of the target RNAhas been inhibited long enough to reduce the levels of the undesirableprotein. This period of time varies between hours to days depending uponthe disease state. These nucleic acid molecules should be resistant tonucleases in order to function as effective intracellular therapeuticagents. Improvements in the chemical synthesis of nucleic acid moleculesdescribed in the instant invention and in the art have expanded theability to modify nucleic acid molecules by introducing nucleotidemodifications to enhance their nuclease stability as described above.

In another embodiment, nucleic acid catalysts having chemicalmodifications that maintain or enhance enzymatic activity are provided.Such nucleic acids are also generally more resistant to nucleases thanunmodified nucleic acid. Thus, in a cell and/or in vivo the activity ofthe nucleic acid may not be significantly lowered. As exemplified hereinsuch enzymatic nucleic acids are useful in a cell and/or in vivo even ifactivity over all is reduced 10 fold (Burgin et al., 1996, Biochemistry,35, 14090). Such enzymatic nucleic acids herein are said to “maintain”the enzymatic activity of an all RNA ribozyme or all DNA DNAzyme.

In another aspect the nucleic acid molecules comprise a 5′ and/or a3′-cap structure.

The term “cap structure” as used herein refers to chemicalmodifications, which have been incorporated at either terminus of theoligonucleotide (see for example Wincott et al., WO 97/26270,incorporated by reference herein). These terminal modifications protectthe nucleic acid molecule from exonuclease degradation, and can help indelivery and/or localization within a cell. The cap can be present atthe 5′-terminus (5′-cap) or at the 3′-terminus (3′-cap) or can bepresent on both termini. In non-limiting examples, the 5′-cap includesinverted abasic residue (moiety), 4′,5′-methylene nucleotide;1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide, carbocyclicnucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides;alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage;threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide,3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety;3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety;1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexylphosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; orbridging or non-bridging methylphosphonate moiety (for more details seeWincott et al., International PCT publication No. WO 97/26270,incorporated by reference herein).

In another embodiment the 3′-cap includes, for example 4′,5′-methylenenucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide,carbocyclic nucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propylphosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate;1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitolnucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide;phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seconucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentylnucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasicmoiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediolphosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate,phosphorothioate and/or phosphorodithioate, bridging or non bridgingmethylphosphonate and 5′-mercapto moieties (for more details seeBeaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by referenceherein).

The term “non-nucleotide”, “non-nucleoside” or “non-nucleosidic” as usedherein refers to any group or compound which can be incorporated into anucleic acid chain in the place of one or more nucleotide units,including either sugar and/or phosphate substitutions, and allows theremaining bases to exhibit their enzymatic activity. The group orcompound is abasic in that it does not contain a commonly recognizednucleotide base, such as adenine, guanine, cytosine, uracil or thymine.

In one embodiment, the invention features modified enzymatic nucleicacid molecules with phosphate backbone modifications comprising one ormore phosphorothioate, phosphorodithioate, methylphosphonate,morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide,sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/oralkylsilyl, substitutions. For a review of oligonucleotide backbonemodifications see Hunziker and Leumann, 1995, Nucleic Acid Analogues:Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417, andMesmaeker et al., 1994, Novel Backbone Replacements forOligonucleotides, in Carbohydrate Modifications in Antisense Research,ACS, 24-39. These references are hereby incorporated by referenceherein.

In connection with 2′-modified nucleotides as described for the presentinvention, by “amino” is meant 2′-NH₂ or 2′-O—NH₂, which can be modifiedor unmodified. Such modified groups are described, for example, inEckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., WO98/28317, respectively, which are both incorporated by reference intheir entireties.

Various modifications to nucleic acid (e.g., antisense and enzymaticnucleic acid molecule) structure can be made to enhance the utility ofthese molecules. For example, such modifications can enhance shelf life,half-life in vitro, stability, and ease of introduction of sucholigonucleotides to the target site, including e.g., enhancingpenetration of cellular membranes and conferring the ability torecognize and bind to targeted cells.

Use of these molecules can lead to better treatment of the diseaseprogression by affording the possibility of combination therapies (e.g.,multiple enzymatic nucleic acid molecules targeted to different genes,enzymatic nucleic acid molecules coupled with known small moleculeinhibitors, or intermittent treatment with combinations of enzymaticnucleic acid molecules (including different enzymatic nucleic acidmolecule motifs) and/or other chemical or biological molecules). Thetreatment of patients with nucleic acid molecules can also includecombinations of different types of nucleic acid molecules. Therapies canbe devised which include a mixture of enzymatic nucleic acid molecules(including different enzymatic nucleic acid molecule motifs), antisenseand/or 2-5A chimera molecules to one or more targets to alleviatesymptoms of a disease.

Diagnostic Uses

The nucleic acid molecules of this invention (e.g., ribozymes) can beused as diagnostic tools to examine genetic drift and mutations withindiseased cells or to detect the presence of RNA in a cell. The closerelationship between enzymatic nucleic acid molecule activity and thestructure of the target RNA allows the detection of mutations in anyregion of the molecule which alters the base-pairing andthree-dimensional structure of the target RNA. By using multipleenzymatic nucleic acid molecules described in this invention, one canmap nucleotide changes which are important to RNA structure and functionin vitro, as well as in cells and tissues. Cleavage of target RNAs withenzymatic nucleic acid molecules can be used to inhibit gene expressionand define the role (essentially) of specified gene products in theprogression of disease. In this manner, other genetic targets can bedefined as important mediators of the disease. These experiments willlead to better treatment of the disease progression by affording thepossibility of combinational therapies (e.g., multiple enzymatic nucleicacid molecules targeted to different genes, enzymatic nucleic acidmolecules coupled with known small molecule inhibitors, or intermittenttreatment with combinations of enzymatic nucleic acid molecules and/orother chemical or biological molecules). Other in vitro uses ofenzymatic nucleic acid molecules of this invention are well known in theart, and include detection of the presence of mRNAs associated with adisease-related condition. Such RNA is detected by determining thepresence of a cleavage product after treatment with an enzymatic nucleicacid molecule using standard methodology.

In a specific example, enzymatic nucleic acid molecules which can cleaveonly wild-type or mutant forms of the target RNA are used for the assay.The first enzymatic nucleic acid molecule is used to identify wild-typeRNA present in the sample and the second enzymatic nucleic acid moleculewill be used to identify mutant RNA in the sample. As reaction controls,synthetic substrates of both wild-type and mutant RNA can be cleaved byboth enzymatic nucleic acid molecules to demonstrate the relativeenzymatic nucleic acid molecule efficiencies in the reactions and theabsence of cleavage of the “non-targeted” RNA species. The cleavageproducts from the synthetic substrates can also serve to generate sizemarkers for the analysis of wild-type and mutant RNAs in the samplepopulation. Thus each analysis can involve two enzymatic nucleic acidmolecules, two substrates and one unknown sample which will be combinedinto six reactions. The presence of cleavage products will be determinedusing an RNAse protection assay so that full-length and cleavagefragments of each RNA can be analyzed in one lane of a polyacrylamidegel. It is not absolutely required to quantify the results to gaininsight into the expression of mutant RNAs and putative risk of thedesired phenotypic changes in target cells. The expression of mRNA whoseprotein product is implicated in the development of the phenotype isadequate to establish risk. If probes of comparable specific activityare used for both transcripts, then a qualitative comparison of RNAlevels will be adequate and will decrease the cost of the initialdiagnosis. Higher mutant form to wild-type ratios will be correlatedwith higher risk whether RNA levels are compared qualitatively orquantitatively.

Additional Uses

Potential usefulness of sequence-specific enzymatic nucleic acidmolecules of the instant invention might have many of the sameapplications for the study of RNA that DNA restriction endonucleaseshave for the study of DNA (Nathans et al., 1975 Ann. Rev. Biochem.44:273). For example, the pattern of restriction fragments could be usedto establish sequence relationships between two related RNAs, and largeRNAs could be specifically cleaved to fragments of a size more usefulfor study. The ability to engineer sequence specificity of the enzymaticnucleic acid molecule is ideal for cleavage of RNAs of unknown sequence.Applicant describes the use of nucleic acid molecules to down-regulategene expression of target genes in bacterial, microbial, fungal, viral,and eukaryotic systems including plant, or mammalian cells.

EXAMPLES

The following are non-limiting examples showing the synthesis of spacersof the present invention and their use for the synthesis ofoligonucleotides and the use of an inline mixer for the improvement ofoligonucleotide synthesis.

Example 1 Synthesis of 20 Atom CPG (Controlled Pore Glass),Urea-dodecylamine (UDDA)

p-Nitrophenyl chloroformate (4.8 g, 23 mmol) was dissolved in a mixtureof CH₂Cl₂ (150 ml) and anhydrous pyridine (20 ml) (FIG. 7). AminopropylCPG (20 g, Prime Synthesis, 631 A°, Amine loading 180 μmoles/g), whichwas the chosen solid support material, was then added to this solutionand the mixture was gently rotated for 3-4 hours at room temperature.The support was then filtered, washed with CH₂Cl₂ several times,followed by treatment with ether and dried. 20 mg of the solid supportwas submitted for loading test (described below) carried out by theaddition of 0.2M NaOH (20 ml). The p-nitrophenolate anion liberated wasmonitored at 400 nm (e=17,000). The concentration of p-nitrophenolateonto this support was 200 μmole/gram of CPG.

Capping: Unreacted amine was capped by reacting the support with aceticanhydride/pyridine (100 ml, 1:1) for 30 minutes. The support wasfiltered, washed several times with CH₃CN, CH₂Cl₂ and ether and dried.

The spacer, 1,12-Dodecyldiamine (1.45 g, 7.25 mmol) was dissolved inCH₂Cl₂ (100 ml) and dry pyridine (10 ml). Solid support from theprevious step was added to this solution and the yellow mixture wasshaken gently overnight. The support was then filtered, sequentiallywashed several times with CH₃OH, CH₃CN, CH₂Cl₂ and ether and dried underreduced pressure. Diamine loading was quantitative.

Loading: The UDDA CPG support, was derivatized in CH₂Cl₂ (100 ml) by thesequential loading of 3′-O-Dimethoxytritylabasic-5′-succinate (abasicsuccinate) (1.34 g, 2.16 mmoles) (terminal oligoribonucleotide group),diisopropylcarbodiimide (0.5 ml) and DMAP (0.4 g) which were thenallowed to rotate very slowly at room temperature for 3 hours. Thesupport was then filtered, washed with CH₃CN, CH₂Cl₂ and ether anddried.

Abasic succinate loading was assayed by determining the amount ofdimethoxytrityl cation released by acidic treatment of a sample of thesupport. An aliquot of approximately 10 mg of the derivatized supportwas weighed, and then reacted with perchloric acid solution (10 ml, 70%HClO₄ 51.4 ml+MeOH 46 ml). The absorbance of the compound was measuredat 498 nm and the amount of bound linker in umol/g of support, wasdetermined by using the following formula:

$\frac{{Absorbance}\mspace{14mu} {at}\mspace{14mu} 498\mspace{14mu} {nm} \times {vol}\mspace{14mu} ({ml})\mspace{14mu} {of}\mspace{14mu} {HClO}_{4}\mspace{14mu} {soln} \times 14.3}{{wt}\mspace{14mu} {of}\mspace{14mu} {support}\mspace{14mu} ({mg})}$

Using the above measurements, the linker loading was determined to be 65μmol/g.

The unreacted amines were capped with acetonitrile (100 ml) containing2,6-lutidine (5 ml), acetic anhydride (5 ml) and NMI (20 ml) for 3 min.The support was filtered, washed with CH₃OH, CH₃CN, CH₂Cl₂ and ether anddried. The loading of the support was 58-60 μmole/g. The chemicalstructure of the UDDA spacer is shown in FIG. 2.

Example 2 Synthesis of 19 Atom CPG, PEG-CPG

Tetraethylene glycol CPG support was prepared by following the sameprocedure as described in example 1, but tetraethyleneglycol diamine wasused as the starting material rather than 1,12-dodecyl diamine. Thechemical reactions are shown in FIG. 6. Final abasic loading on thissupport was 50 μmoles/g. The chemical structure for the PEG spacer isshown in FIG. 2.

Tetraethyleneglycol diamine was synthesized in two steps fromtetraethyleneglycol ditosylate. The ditosylate (50 g, 99.5 mmoles) wasdissolved in dry DMF (250 ml) and sodium azide (19.5 g, 350 mmoles) wasadded. The reaction mixture was heated at 100° C. for 16 h. The mixturewas concentrated and then triturated with CH₂Cl₂. The solid wasfiltered, washed several times with CH₂Cl₂ and the combined washings wasevaporated to dryness under reduced pressure. The product,tetraethyleneglycol diazide was distilled under vacuum at 180° C. bathtemperature. The protocol gave a product yield of 93%.

This compound was hydrogenated using H₂/10% Pd/C(800 mg) in ethylacetate(150 ml). The catalyst was filtered, washed with ethylacetate and dried(MgSO₄). Evaporation of the solvent under reduced pressure afforded thediamine in 97% yield.

Example 3 Synthesis of 22 Atom CPG, HHDA

16-Hydroxyhexadecanoic acid (10.112 g, 37.12 mmol) was coevaporated withdry pyridine (3×30 ml) and then dissolved in dry pyridine (100 ml) (FIG.5). To this stirred ice cold mixture, a solution of DMTCl (16.35 g,48.25 mmol) in dry pyridine (100 ml) was added dropwise and the reactionmixture was allowed to stir at room temperature overnight. The reactionmixture was then cooled to 0° C., a solution of pentafluorophenol (9.56g, 51.97 mmol) dissolved in a mixture of CH₂Cl₂ (50 ml) and pyridine (15ml) was added drop-wise to the reaction mixture with stirring. Afteranother hour, dicyclohexylcarbodiimide (10.72 g, 51.97 mmol) in CH₂Cl₂(70 ml) was added dropwise and the reaction mixture was left stirring atroom temperature overnight. Precipitated N,N-dicyclohexylurea wasfiltered and the residue was washed with CH₂Cl₂. The combined washingswas evaporated to dryness, redissolved in CH₂Cl₂ (200 ml), washed with5% NaHCO₃ (100 ml) and dried over Na₂SO₄. The crude product was used assuch for the next reaction.

To a solution of the above ester (0.7 g), in a mixture of dry THF (50ml) and dry pyridine (5 ml), aminopropyl CPG amine (10 g, PrimeSynthesis, pore size 630 A°, bulk density 0.26 g/cc, specific surfacearea 86.6 m²/g, pore volume 1.68 cc/g, particle size 80-200 mesh,initial loading 174 umol/g) was added slowly. The mixture was rotatedvery gently for a day and the solid was filtered, washed with CH₃CN andCH₂Cl₂, dried in air and then under high vacuum.

The addition of the linker was assayed by determining the amount ofdimethoxytrityl cation released by acidic treatment of a sample of thesupport, as mentioned earlier. The addition of N,N-dicyclohexylurea wasfound to be 85-90 umol/g. Subsequent capping and loading of abasicsuccinate was performed as in example 1. The loading of abasic succinatewas calculated using the formula described above, which was 56 μmol/g.The chemical structure of 22 atom CPG, HHDA is given in FIG. 2.

Example 4 Synthesis of 13 Atom CPG, C9

Native CPG was silanized with N-(6-aminohexyl)aminopropyl trimethoxysilane according to the following procedure. CPG (2 L) was suspended ina 3% solution of N-(6-aminohexyl)aminopropyl trimethoxy silane inanhydrous toluene (4 L) and the mixture refluxed for 8-12 hours withslow stirring. The cooled suspension was then filtered and the supportwashed with toluene and dried under reduced pressure.

Loading (FIG. 9): The C9 CPG support, was derivatized in CH₂Cl₂ (100 ml)by the sequential loading of 3′-O-Dimethoxytritylabasic-5′-succinate(abasic succinate) (1.34 g, 2.16 mmoles) (terminal oligoribonucleotidegroup), diisopropylcarbodiimide (0.5 ml) and DMAP (0.4 g) which werethen allowed to rotate very slowly at room temperature for 3 hours. Thesupport was then filtered, washed with CH₃CN, CH₂Cl₂ and ether anddried.

Abasic succinate loading was assayed by determining the amount ofdimethoxytrityl cation released by acidic treatment of a sample of thesupport. An aliquot of approximately 10 mg of the derivatized supportwas weighed, and then reacted with perchloric acid solution (10 ml, 70%HClO₄ 51.4 ml+MeOH 46 ml). The absorbance of the compound was measuredat 498 nm and the amount of bound linker in umol/g of support, wasdetermined by using the following formula:

$\frac{{Absorbance}\mspace{14mu} {at}\mspace{14mu} 498\mspace{14mu} {nm} \times {vol}\mspace{14mu} ({ml})\mspace{14mu} {of}\mspace{14mu} {HClO}_{4}\mspace{14mu} {soln} \times 14.3}{{wt}\mspace{14mu} {of}\mspace{14mu} {support}\mspace{14mu} ({mg})}$

Using the above measurements, the linker loading was determined to be 75μmol/g.

The unreacted amines were capped with acetonitrile (100 ml) containing2,6-lutidine (5 ml), acetic anhydride (5 ml) and NMI (20 ml) for 3 min.The support was filtered, washed with CH₃OH, CH₃CN, CH₂Cl₂ and ether anddried. The loading of the support was 58-60 μmole/g. The chemicalstructure of the UDDA spacer is shown in FIG. 2.

Example 5 Synthesis of Ribozyme

A ribozyme having the sequence:g_(s)a_(s)g_(s)u_(s)ugcUGAuGaggccgaaaggccGaaAgucugB (Angiozyme™) (SEQ IDNO: 1) was prepared on UDDA, PEG, and HDDA spacers linked to CPG, whereg, a, u and c stands for 2′-O-methyl guanosine, adenosine, uridine, andcytidine respectively, U stands for 2′-C-allyl uridine, A and G standsfor adenosine and guanosine respectively, s stands for phosphorothioatelinkages and B stands for 3′-3′ inverted abasic moiety. The synthesiswas carried out on Pharmacia OligoPilot II automated synthesizer using5′-DMT-2′-O-methyl-N²-tert-butyl-phenoxyacetylguanosine and5′-DMT-2′-O-methyl-N⁶-tert-butylphenoxyacetyl-adenosine,DMT-2′-O-TBDMS-N⁶-tert-butylphenoxy-acetyl-adenosine3′-N,N-diisopropyl-(2-cyanoethyl)phosphoramidites and2′-O-methyl-5′-DMT-N⁴-acetylcytidine, 2′-O-methyl-5′-DMT-uridine,2′-C-allyl-5′-DMT-uridine3′-N,N-diisopropyl-(2-cyanoethyl)-phosphoramidites. The synthesis cyclewas as follows. The activator, 5-(ethylthio)-1H-tetrazole was formulatedas 0.5M solution in CH₃CN and phosphoramidite was formulated as 0.15Msolution in CH₃CN. The syntheses were carried out using controlled poreglass (CPG) support of 600 Å pore size, 80-120 mesh, and 50-60 μmol/gloading with 5′-abasic succinate. Conditions for each step of synthesisis given in Table II.

Detritylation was achieved using Dichloroacetic acid in CH₂Cl₂ (3% v/v,Burdick & Jackson), the amounts used were determined by conductivityfeedback, followed by 1.5 column volumes of CH₃CN as a wash and another1.5 column volumes of the detritylation solution. During the couplingstep, 1.5 equivalents of nucleoside phosphoramidite was used forcoupling of 2′-O-methyl (for 10 minutes) or 2.1 equivalents ofnucleoside phosphoramidite was used for 2′-OH or 2′-C-allyl coupling (20minutes). Equivalents are based on the moles of CPG bound 3′-terminalnucleoside. 8 equivalents of S-ethyl tetrazole (activator) was used toactivate the phosphoramidites. Activator equivalents were based onmolecules of nucleoside phosphoramidite. Oxidation of the phosphite bondto phosphate bond was accomplished using 0.05 M I₂ in 90:10pyridine:water (Burdick & Jackson) with a contact time of 1 minute.Phosphorothioate internucleotide linkages were synthesized bysulfurization with 0.5 M Beaucage reagent for 3 minutes. And finallycapping was achieved by using 6.3 equivalents of cap A (20% N-methylimidazole, 80% CH₃CN) or 9.0 equivalents of cap B (20% acetic anhydride,30% 2,6-lutidine, 50% CH₃CN).

The last trityl was left on the solid support. The support was dried andsuspended in 1:1 33% methylamine/EtOH:dry DMSO (160 ml) and the mixturewas allowed to shake at room temperature for 90 minutes. The reactionmixture was then quickly filtered, washed with dry DMSO (4×15 ml) andthe combined washings was transferred to a Schott bottle. The solutionwas then cooled at −78° C. for a short time and to this cool solutionTEA.3HF (80 ml) was added slowly. The reaction mixture was allowed toshake at 65° C. for 1 h in an incubated shaker. The bottle was thenremoved and cooled at −78° C. till the solution became a frozen slurry.1.5M ammonium bicarbonate solution was then slowly added to the reactionmixture with periodic mixing. The material is then quantitated by UV at260 nm and analyzed by HPLC. The HPLC chromatograph for ribozymesynthesized on CPG linked HHDA spacer is shown in FIG. 3. The absorbancefor the product was 240 optical density units (ODU)/μmol of the crudereaction. The results for ribozyme synthesized on CPG linked UDDA andPEG spacer is shown in FIG. 4. The ribozyme on the PEG spacer and theUDDA spacer yield 290 and 266 ODU per μmol of crude reaction,respectively. A similar synthesis run on a 150 mmol scale using 3equivalents of S-ethyl tetrazole (activator) resulted in 83% full lengthribozyme based on CGE analysis of crude deprotected material.

Example 6 Synthesis of Ribozyme Using 13 Atom CPG, C9

A ribozyme having the sequence:g_(s)a_(s)g_(s)u_(s)ugcUGAuGaggccgaaaggccGaaAgucugB (Angiozyme™) (SEQ IDNO: 1) was prepared on the 13 atom CPG C9 spacer on a 200 umol scale,where g, a, u and c stands for 2′-O-methyl guanosine, adenosine,uridine, and cytidine respectively, U stands for 2′-C-allyl uridine, Aand G stands for adenosine and guanosine respectively, s stands forphosphorothioate linkages and B stands for 3′-3′ inverted abasic moiety.The synthesis was carried out on Pharmacia OligoPilot II or AKTAautomated synthesizer using 5′-DMT-2′-O-methyl-N²-isobutyryl guanosine,5′-DMT-2′-O-methyl-N⁶-benzoyl adenosine,3′-N,N-diisopropyl-(2-cyanoethyl)phosphoramidites and2′-O-methyl-5′-DMT-N⁴-acetylcytidine, 2′-O-methyl-5′-DMT-uridine,2′-C-allyl-5′-DMT-uridine3′-N,N-diisopropyl-(2-cyanoethyl)-phosphoramidites. The synthesis cyclewas as follows. The activator, 5-(ethylthio)-1H-tetrazole was formulatedas 0.5M solution in CH₃CN and phosphoramidite was formulated as 0.15Msolution in CH₃CN. The syntheses were carried out using controlled poreglass (CPG) support of 600 Å pore size, 80-120 mesh, and 50-60 μmol/gloading with 5′-abasic succinate using the 13 atom C9 linker of theinvention.

Detritylation was achieved using Dichloroacetic acid in CH₂Cl₂ (3% v/v,Burdick & Jackson), the amounts used were determined by conductivityfeedback, followed by 1.5 column volumes of CH₃CN as a wash and another1.5 column volumes of the detritylation solution. During the couplingstep, 1.5 equivalents of nucleoside phosphoramidite was used forcoupling of 2′-O-methyl (for 10 minutes) or 2.1 equivalents ofnucleoside phosphoramidite was used for 2′-OH or 2′-C-allyl coupling (20minutes). Equivalents are based on the moles of CPG bound 3′-terminalnucleoside. 8 equivalents of S-ethyl tetrazole (activator) was used toactivate the phosphoramidites. Activator equivalents were based onmolecules of nucleoside phosphoramidite. Oxidation of the phosphite bondto phosphate bond was accomplished using 0.05 M I₂ in 90:10pyridine:water (Burdick & Jackson) with a contact time of 1 minute.Phosphorothioate internucleotide linkages were synthesized bysulfurization with 0.5 M Beaucage reagent for 3 minutes. And finallycapping was achieved by using 6.3 equivalents of cap A (20% N-methylimidazole, 80% CH₃CN) or 9.0 equivalents of cap B (20% acetic anhydride,30% 2,6-lutidine, 50% CH₃CN).

The last trityl was left on the solid support. The support was dried andsuspended in 1:1 33% methylamine/EtOH:dry DMSO (160 ml) and the mixturewas allowed to shake at room temperature for 90 minutes. The reactionmixture was then quickly filtered, washed with dry DMSO (4×15 ml) andthe combined washings was transferred to a Schott bottle. The solutionwas then cooled at −78° C. for a short time and to this cool solutionTEA.3HF (80 ml) was added slowly. The reaction mixture was allowed toshake at 65° C. for 1 h in an incubated shaker. The bottle was thenremoved and cooled at −78° C. till the solution became a frozen slurry.1.5M ammonium bicarbonate solution was then slowly added to the reactionmixture with periodic mixing. The material was then quantitated by UV at260 nm and analyzed by CGE. The CGE chromatograph for ribozymesynthesized on CPG linked C9 spacer is shown in FIG. 10. This synthesison the C9 spacer provided 212 ODU per μmol of crude reaction.

Example 7 Synthesis of Ribozyme Using 13 Atom CPG, C9 Using Method E

A ribozyme having the sequence:g_(s)a_(s)g_(s)u_(s)ugcUGAuGaggccgaaaggccGaaAgucugB (Angiozyme™) (SEQ IDNO: 1) is prepared on the 13 atom CPG C9 spacer on a 200 umol scaleaccording to Method E (see for example FIG. 11), where g, a, u and cstands for 2′-O-methyl guanosine, adenosine, uridine, and cytidinerespectively, U stands for 2′-C-allyl uridine, A and G stands foradenosine and guanosine respectively, s stands for phosphorothioatelinkages and B stands for 3′-3′ inverted abasic moiety. The synthesis iscarried out on Pharmacia OligoPilot II or AKTA automated synthesizerusing 5′-DMT-2′-O-methyl-N²-isobutyryl guanosine,5′-DMT-2′-O-methyl-N⁶-benzoyl adenosine, and2′-O-methyl-5′-DMT-N⁴-acetylcytidine, 2′-O-methyl-5′-DMT-uridine,2′-C-allyl-5′-DMT-uridine nucleosides bearing a free 3′-hydroxyl. Thesynthesis cycle is as follows. The activator, 5-(ethylthio)-1H-tetrazoleis formulated as 0.5M solution in CH₃CN and phosphoramidite(2-cyanoethyl tetraisopropylphosphorodiamidite) is formulated as 0.15Msolution in CH₃CN. The syntheses are carried out using controlled poreglass (CPG) support of 600 Å pore size, 80-120 mesh, and 50-60 μmol/gloading with 5′-abasic succinate using the 13 atom C9 linker of theinvention.

Detritylation (step A, FIG. 11) is achieved using Dichloroacetic acid inCH₂Cl₂ (3% v/v, Burdick & Jackson), the amounts used are determined byconductivity feedback, followed by 1.5 column volumes of CH₃CN as a washand another 1.5 column volumes of the detritylation solution. Theactivation step (step B, FIG. 11) features the used of 2-cyanoethyltetraisopropylphosphorodiamidite (2.0 equivalents) and5-(ethylthio)-1H-tetrazole (8.0 equivalents) with a coupling time of 20minutes per cycle. Following activation, coupling (step C, FIG. 11) ofnucleoside (1.5 equivalents) in the presence of5-(ethylthio)-1H-tetrazole (1.5 equivalents) takes place over anadditional 20 minutes. Activator equivalents are based on molecules ofnucleoside phosphoramidite. Oxidation (step D, FIG. 11) of the phosphitebond to phosphate bond is accomplished using 0.05 M I₂ in 90:10pyridine:water (Burdick & Jackson) with a contact time of 1 minute.Phosphorothioate internucleotide linkages are synthesized bysulfurization with 0.5 M Beaucage reagent for 3 minutes. And finallycapping (step E, FIG. 11) is achieved by using 6.3 equivalents of cap A(20% N-methyl imidazole, 80% CH₃CN) or 9.0 equivalents of cap B (20%acetic anhydride, 30% 2,6-lutidine, 50% CH₃CN).

The last trityl is left on the solid support. The support is dried andsuspended in 1:1 33% methylamine/EtOH:dry DMSO (160 ml) and the mixtureis allowed to shake at room temperature for 90 minutes. The reactionmixture is then quickly filtered, washed with dry DMSO (4×15 ml) and thecombined washings are transferred to a Schott bottle. The solution isthen cooled at −78° C. for a short time and to this cooled solutionTEA.3HF (80 ml) is added slowly. The reaction mixture is allowed toshake at 65° C. for 1 h in an incubated shaker. The bottle is thenremoved and cooled at −78° C. till the solution became a frozen slurry.1.5M ammonium bicarbonate solution is then slowly added to the reactionmixture with periodic mixing. The material is then quantitated by UV at260 nm and analyzed by CGE.

Example 8 Incorporation of Inline Mixer

Introduction of inline mixer: Five experiments were performed at the 182μmol scale. All syntheses were done using standard protectedphosphoramidites (iBuG/BzA). The runs are summarized as follows: 8:1(S-ethyl tetrazole) SET control (no mixer), 8:1 SET mixer, 6:1 control,6:1 mixer, and 8:1 mixer (p-50). The mixer used was 1.9 mL inline mixerfrom Komax. Mixer placement was between port 4 and valve 5 in all mixerruns except the last run (p-50) were the mixer was placed betweenpost-p-50 pump and valve 6. Control runs used no mixer. Phosphoramiditeequivalent was 1.5/2.1 for 2′-O-Me/RNA for all syntheses. Results of allfive syntheses are summarized in Table III a.

GMP inline mixer runs: Two experimental runs were done along withcontrols in the cGMP facility at the 3000 μmol scale. The firstexperimental run was done using the standard 2.1 phosphoramiditeequivalents using an 8:1 ratio of SET with the 11.1 mL inline-mixer(port 4/valve 5). Standard 3000 μmol delivery styles were maintained inthis run, including the 2× volume phosphoramidite approach for allbases.

The second experimental run was done using a modified coupling cyclewith the 11.1 mL mixer (port 4/valve 5). For both 2′-O-Me and RNA 1.9equivalents of phosphoramidite were used with an 8:1 ratio of SET:PA.However, a 1× volume phosphoramidite delivery approach was used for allbases.

For both of the above runs, controls were run concomitantly to theexperimental runs. Results from small scale deprotection are summarizedin Table III ( ) indicates normalized backside. All phosphoramiditesused were PAC (phenoxyacetyl) protected. Results for these syntheses aresummarized in Table III b.

The term “SET” as used herein refers to S-ethyl tetrazole activator.

The terms “iBuG” and “BzA” as used herein refers to isobutyryl Gphosphoramidite and benzoyl A phosphoramidite respectively.

The term “PAC” as used herein refers to phenoxyacetyl protection ofexocyclic amine functions.

The term “2′-O-Me” as used herein refers to 2′-O-methylribonucleosides

The term “RNA” as used herein refers to a molecule comprising at leastone ribonucleotide residue. By “ribonucleotide” or “2′-OH” is meant anucleotide with a hydroxyl group at the 2′ position of aβ-D-ribo-furanose moiety.

The term “port 4/valve 5” as used herein refers to instrument ports andvalves on the Pharmacia Oligo Pilot II synthesizer.

The term “CGE FLP” as used herein refers to capillary gelelectrophoresis determined % full length product.

The term “CGE Backside (n+1)” as used herein refers to capillary gelelectrophoresis determined % backside impurity.

The term “CGE Frontside (n−1)” as used herein refers to capillary gelelectrophoresis determined % frontside impurity.

All patents and publications mentioned in the specification areindicative of the levels of skill of those skilled in the art to whichthe invention pertains. All references cited in this disclosure areincorporated by reference to the same extent as if each reference hadbeen incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those inherent therein. The methodsand compositions described herein as presently representative ofpreferred embodiments are exemplary and are not intended as limitationson the scope of the invention. Changes therein and other uses will occurto those skilled in the art, which are encompassed within the spirit ofthe invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varyingsubstitutions and modifications can be made to the invention disclosedherein without departing from the scope and spirit of the invention.Thus, such additional embodiments are within the scope of the presentinvention and the following claims.

The invention illustratively described herein suitably can be practicedin the absence of any element or elements, limitation or limitationsthat is not specifically disclosed herein. Thus, for example, in eachinstance herein any of the terms “comprising”, “consisting essentiallyof” and “consisting of” can be replaced with either of the other twoterms. The terms and expressions which have been employed are used asterms of description and not of limitation, and there is no intentionthat in the use of such terms and expressions of excluding anyequivalents of the features shown and described or portions thereof, butit is recognized that various modifications are possible within thescope of the invention claimed. Thus, it should be understood thatalthough the present invention has been specifically disclosed bypreferred embodiments, optional features, modification and variation ofthe concepts herein disclosed can be resorted to by those skilled in theart, and that such modifications and variations are considered to bewithin the scope of this invention as defined by the description and theappended claims.

In addition, where features or aspects of the invention are described interms of Markush groups or other grouping of alternatives, those skilledin the art will recognize that the invention is also thereby describedin terms of any individual member or subgroup of members of the Markushgroup or other group.

Other embodiments are within the following claims.

TABLE I Reagent Equivalents Amount Wait Time* DNA Wait Time* 2′-O-methylWait Time* RNA A. 2.5 μmol Synthesis Cycle ABI 394 InstrumentPhosphoramidites 6.5 163 μL 45 sec 2.5 min 7.5 min S-Ethyl Tetrazole23.8 238 μL 45 sec 2.5 min 7.5 min Acetic Anhydride 100 233 μL 5 sec 5sec 5 sec N-Methyl 186 233 μL 5 sec 5 sec 5 sec Imidazole TCA 176 2.3 mL21 sec 21 sec 21 sec Iodine 11.2 1.7 mL 45 sec 45 sec 45 sec Beaucage12.9 645 μL 100 sec 300 sec 300 sec Acetonitrile NA 6.67 mL NA NA NA B.0.2 μmol Synthesis Cycle ABI 394 Instrument Phosphoramidites 15 31 μL 45sec 233 sec 465 sec S-Ethyl Tetrazole 38.7 31 μL 45 sec 233 min 465 secAcetic Anhydride 655 124 μL 5 sec 5 sec 5 sec N-Methyl 1245 124 μL 5 sec5 sec 5 sec Imidazole TCA 700 732 μL 10 sec 10 sec 10 sec Iodine 20.6244 μL 15 sec 15 sec 15 sec Beaucage 7.7 232 μL 100 sec 300 sec 300 secAcetonitrile NA 2.64 mL NA NA NA C. 0.2 μmol Synthesis Cycle 96 wellInstrument Equivalents: DNA/ Amount: DNA/2′-O- Wait Time* 2′-O- Reagent2′-O-methyl/Ribo methyl/Ribo Wait Time* DNA methyl Wait Time* RiboPhosphoramidites   22/33/66 40/60/120 μL 60 sec 180 sec 360 sec S-EthylTetrazole   70/105/210 40/60/120 μL 60 sec 180 min 360 sec AceticAnhydride  265/265/265 50/50/50 μL 10 sec 10 sec 10 sec N-Methyl 502/502/502 50/50/50 μL 10 sec 10 sec 10 sec Imidazole TCA  238/475/475250/500/500 μL 15 sec 15 sec 15 sec Iodine  6.8/6.8/6.8 80/80/80 μL 30sec 30 sec 30 sec Beaucage   34/51/51 80/120/120 100 sec 200 sec 200 secAcetonitrile NA 1150/1150/1150 μL NA NA NA Wait time does not includecontact time during delivery.

TABLE II Step Reagent Equivalents* Reaction Time DetritylationDichloroacetic acid in Conductivity feedback, N/A CH₂Cl₂ (3% v/v,Burdick & followed by 1.5 CV Jackson) CH₃CN wash and another 1.5 CVdetrit solution Coupling Nucleoside phosphoramidites 1.5 for2′-O-methyl's & 10 min (2′-O-Methyls) 2.1 for RNA/2′-C-allyl Activator8** 20 min (ribo & 2′-C- allyl) Sulfurization 0.5 M Beaucage reagent 7.53.0 min Contact time Oxidation 0.05 M I₂ in 90:10 4.0 1 min contact timepyridine:water (Burdick & Jackson Capping Cap A: 20% NMI, 80% 6.3 0.5min contact time CH₃CN Cap B: 20% Ac2O, 30% 2,6- 9.0 lutidine, 50% CH₃CN*Equivalents are based on the moles of CPG-bound 3′-terminal nucleoside.**Activator equivalents are based on moles of nucleosidephosphoramidite.

TABLE III Results of incorporating inline mixer. CGE Backside CGEFrontside Synthesis CGE FLP (n + 1) (n − 1) a. 8:1 control 77.4  6.7(7.97) 5.0 8:1 mixer 81.3 6.4 (7.3) 2.6 6:1 control 75.0  6.3 (7.75) 4.56:1 mixer 81 5.7 (6.1) 2.1 8:1 mixer(p-50) 83.5 4.1 (4.7) 2.7 b. Run #1control 67.3 14.6 (17.8) 3.7 (GMP223) Run #1 mixer 72.1 11.4 (13.6) 3.3(GMP226) Run #2 control 69.4 12.7 (15.5) 4.4 (GMP229) Run #2 mixer 77.27.9 (9.3) 3.7 (GMP232)

1. A method for oligonucleotide synthesis comprising: a) 5′-Deblocking;b) Coupling; c) Oxidation; and d) Capping; wherein (a), (b), (c) and (d)are repeated under conditions suitable for the synthesis of theoligonucleotide, and wherein the synthesis of the oligonucleotide iscarried out in the presence of a compound having Formula II:

wherein SP is a solid support, W is selected from the group consistingof a carboxy linkage, an amino linkage, a carboxamido linkage, amercaptoalkyl linkage, a succinyl linkage, an oxalyl linkage, a 3′glycolate termini linkage, an o-nitrophenyl-1,3-propanediol linkage, analkoxybenzylidene acetal linkage, a hydroquinone-O-0′-diacetic acidlinkage, and a pentachlorophenyl-succinate linkage, and B represents aterminal chemical group from which an oligonucleotide can besynthesized.
 2. The method of claim 1, wherein said synthesis is carriedout on a reaction scale of about 0.1 μmol to about 100 μmol.
 3. Themethod of claim 1, wherein said synthesis is carried out on a reactionscale of about 100 μmol to about 1 mmol.
 4. The method of claim 1,wherein said synthesis is carried out on a reaction scale of about 1mmol to about 1 mol.
 5. The method of claim 1, wherein said synthesis iscarried out on a reaction scale of about 1 mol to about 1000 mol.
 6. Themethod of claim 1, wherein said B is linked to the oligonucleotide witha 3′-5′, 3′-2′, or 3′-3′ linkage.